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Abstract 
Through the use of developmental and knock out studies Mig-6 has been shown to have a 
role in development.  It has also been shown to be a tumour suppressor gene. Little work has 
been done as yet looking at its role in the adult. 
This study examined the role of Mig-6 in the lung with the ultimate goal being to determine if 
the pulmonary phenotype due to Mig-6 ablation is due to a developmental programming or 
loss of function in the adult. This was investigated in two ways.  
1. To investigate if knocking out Mig-6 in adult lung has an effect on lung function 
2. Investigate the role of Mig-6 in lung epithelial cells by RNAi (Investigation of the 
Role of Mig-6 in Pulmonary Epithelial Cells and Vascular Cells In Vitro). 
Knocking out Mig-6 in the adult mice showed no difference in epithelial markers and after 
staining morphology and airway size were found to be normal. This would seem to indicate 
that the Mig-6 phenotype is due to altered development of the lungs during the neonatal 
period and not due to a loss of function in the adult. 
From the cell work we observed differences in the effect on epithelial cells vs. endothelial 
cells when Mig-6 was knocked out. The epithelial cells showed an increased number of 
viable cells present after knocking out Mig-6 while the number of viable cells was decreased 
in the endothelial cells. This would indicate that knocking out Mig-6 in epithelial cells causes 
increased proliferation but in endothelial cells causes apoptosis. 
Conclusions: Ablation of Mig-6 leads to increased proliferation in epithelial cells (and 
apoptosis in endothelial cells) but knocking it out in the adult stage has a mild effect on lung 
phenotype 
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1. Introduction 
Mig-6 is an immediate early response gene which is transcriptionally induced by a number of 
factors including growth factors, stress, cytokines and the Ras oncoprotein (1,2,3). This gene 
in only present in higher eukaryotes (4) and can be rapidly induced allowing it to potentially 
involved in early regulation of cellular responses (4). Mig-6 has been shown to be involved in 
the EGF signalling pathway (4) and has been proposed to be involved in the HGF signalling 
pathway as a negative regulator. It has previously shown in our laboratory that Mig-6 levels 
in the lung change throughout development and that Mig-6 has a developmental role (5) so 
the overall aim of our work was to investigate whether Mig-6 also played a role post-natally.  
A Mig-6 knockout mouse (Mig-6-/-) has been developed by the DeMayo lab at Baylor 
College of Medicine where Mig-6 has been knocked out at the germline level which has 
enabled us to look at what occurs during development in the absence of Mig-6 (6). The 
embryo lethal phenotype and multi-tissue carcinogenesis of the Mig-6 null allele make it 
difficult to investigate the impact of ablation of Mig-6 on specific tissues and at specific time 
points during development. A conditional knockout would overcome this.  
Our lab developed an inducible ablation model by crossing Rosa26-Cre-ERT2 mice with 
Mig-6flox/flox mice providing us with a population of Cre positive mice in addition to Cre 
negative mice. Administration of Tamoxifen to Cre positive mice would induce ablation of 
Mig-6 and allow us to look at what effects (if any) this would have on adult mice.   
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1.1 The Lung 
Lung Function 
The lung is a complex organ composed of more than 40 different cell types whose main 
function is in gaseous exchange (7, 8, 9, 10, 11). The various cell types are heterogeneously 
distributed within a highly complex framework of branching that eventually terminates with 
the alveoli. Gaseous exchange occurs across the thin epithelium of the millions of alveoli 
which have a surface area of approx.100m2 which is sufficient to carry out gas exchange for 
the entire body, which is important as every single cell in the body needs a constant supply of 
oxygen in order to produce enough energy to grow, repair or replace itself and to maintain 
vital functions (12). The pulmonary epithelium has a number of functions other than gaseous 
exchange. It provides a protective barrier between the host and the outside environment by 
segregating inhaled foreign agents, and it also controls the movement of solutes and water, 
contributing to the maintenance of lung fluid balance (13). Lung epithelium plays a role in 
the metabolism of endogenous mediators and is capable of regeneration, allowing normal cell 
turnover and restoration of airway and alveolar functions after lung injury. Lung epithelium 
produces surfactant and several proteins which are important as part of the immune defences 
of the body (14).  
Lung Structure:  
The respiratory system (shown in figure 1.1) can be divided into upper and lower. The upper 
respiratory system is comprised of the nasal cavity, paranasal sinuses and the nasopharynx. 
The lower respiratory tract begins at the larynx followed by the trachea which divides to form 
the right and left primary bronchi each of which divides to form secondary (lobar) bronchi 
and then tertiary (segmental) bronchi. Tertiary bronchi divide into numerous bronchioles. The 
terminal bronchioles divide into the respiratory bronchioles, alveolar ducts and alveolar sacs 
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which open into the alveoli. The respiratory epithelium undergoes progressive transition from 
tall, pseudostratified columnar, ciliated form in the larynx and trachea to a simple, cuboidal 
non-ciliated form in the alveoli .   
 
Figure 1.1: diagram illustrating the overall structure of the respiratory system (15) 
It is the alveoli which perform the function of gaseous exchange. The alveolar wall is made 
up of epithelial cells, supporting tissues and blood vessels. The epithelial layer consists of 
type I and type II pneumocytes. Type I pneumocytes are part of the gaseous diffusion barrier 
while the type II pneumocytes secrete surfactant which serves to reduce surface tension in the 
alveoli and prevents alveolar collapse during expiration .  
 
Lung Development: 
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In mammals most of the structural development and maturation of the lung takes place in 
utero (16). In humans, there are four stages of pre-natal lung development (shown in Figure 
1.2): 
1. Embryonic (up to 7 weeks gestation) 
2. Pseudoglandular (5-17 weeks of gestation) 
3. Canalicular (16-27 weeks of gestation) 
4. Alveolar (27 weeks gestation to term) 
 
Figure 1.2: diagram of lung development showing the time points at which different 
structures appear (16). 
During the pseudo glandular phase of lung development, major development events occur in 
which the airway wall cells differentiate into cartilage, sub mucosal gland, bronchial smooth 
muscle and epithelial cell types. The epithelium differentiates into type I and type II 
pneumocytes during the canalicular stage.  
The blood vessel network develops at the same time as the airways. At 28 days gestation, 
groups of endothelial cells can be found in the mesenchyme. At 34 days, capillaries lined by 
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endothelial cells surround the two primitive lung buds. As branching of the developing 
airways proceeds, each new bud is surrounded by a halo of endothelial cells (16).  
Molecular Regulation of Lung Development: 
Genetic factors are critical to early lung morphogenesis and post natal maturation. Alteration 
of any of the essential genes disturbs the regulation of development and results in neonatal 
lung disease and abnormally developed lungs. Abnormally developed lungs have a higher 
propensity towards lung disease such as chronic obstructive pulmonary disease (COPD) and 
asthma. Growth factors mediate tissue interactions and regulate a variety of cellular functions 
that are critical for normal lung development and homeostasis (17). Epidermal growth factor 
(EGF) members have been implicated in the development and maturation of the respiratory 
system in a diverse range of animal species. It has been found that mice deficient in EGF 
receptor (EGFR) show delayed lung maturation which is characterised by poor 
alveolarisation and abnormal branching. Decreased alveolarisation and septation in these 
mice correlates with low expression of surfactant protein C (SP-C) and thyroid specific 
transcription factor (TTF-1) (11). EGF and EGFR are increased in lungs with 
BronchoPulmonary Dysplasia (BPD) and fibrosis. Over-expression of the EGFR ligand and 
tumour growth factor alpha (TGFα) in perinatal lungs causes disrupted alveolarisation and 
vascularisation which leads to fibrosis in adulthood.  
Among the essential factors that regulate lung development, EGF signalling is important for 
both early stage and late- stage lung development. Ablation of EGFR leads to reduced lung 
branching and changed epithelial cells.  
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Lung Disease: 
Lung disease is classed as any disorder where lung function is impaired (18). Lung disease is 
the number three killer (behind heart disease and cancer) in the USA and is responsible for 
one in six deaths. Deaths due to heart disease are falling while in contrast, deaths due to lung 
disease are increasing each year (19). lung disease can occur as a result of a number of 
different factors such as exposure to tobacco smoke (both actively and passively), air 
pollutants, occupational exposure to foreign particles such as silica dust or asbestos, 
carcinogens, infectious agents and overactive immune system defences (18). In many cases 
there is not just one single cause that can be attributed to the lung disease present, often the 
disorder is caused by a number of the factors outlined above. Diseases which affect the 
respiratory system include: obstructive lung diseases like asthma and emphysema, respiratory 
distress syndrome, pulmonary oedema, pulmonary fibrosis and lung cancer. Infectious agents 
affecting the lung include respiratory syncytial virus (RSV), TB, influenza as well as other 
bacteria and viruses (18). Genetic factors may also affect lung function, a well known 
example of this being Cystic Fibrosis. 
Irish Lung disease morbidity and mortality 
Ireland has the highest death rate from respiratory disease in Western Europe (almost twice 
the EU average) with deaths now exceeding those from coronary artery disease. Respiratory 
disease kills one in five people in Ireland. The second most commonly reported long-term 
illnesses in young adults (under 44 years old) are conditions of the respiratory system. Lung 
cancer is the third most common cancer in both men and women. Survival rates for lung 
cancer are very low – the one year survival rate is 23.7% and the five year survival rate is 
8.6%. Respiratory tuberculosis remains a significant problem although the incidence rate per 
100,000 has remained largely unchanged since 2000 (20). Because of the increasing numbers 
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of deaths due to lung disease and the numbers of people living with chronic lung disease it 
has become increasingly important to study the mechanisms involved in both initial 
development and later function of the lung. By looking at what factors control lung function 
and development, we may gain clues as to what goes wrong in different conditions causing 
lung problems. Only by understanding what has gone wrong can we begin to devise solutions 
and potential new treatment options to prolong the life of affected individuals.  
By looking at the signalling pathways which become activated following injury or tissue 
damage we may be able to come up with intervention strategies to limit any damage caused. 
We hypothesised that there may be a re-emergence of the pathways seen in the 
developmental stages in response to lung damage. 
Lung Cancer 
Lung cancer is the fourth most common cancer in Ireland. 20% of all cancer deaths in Ireland 
are from lung cancer and with the indidence among Irish women increasing, it is likely to 
become an even more prevalent disease (21). In theory, lung cancer is an almost preventable 
disease as 85-90% of cases have been attributed to smoking (21, 22) 
The two main types of lung cancer are non-small cell lung cancer (NSCLC) (more common) 
and small cell lung cancer (SCLC) (15). SCLC is highly aggressive, almost always occurs in 
smokers and is rapidly growing. NSCLC is more variable and severity depends on its 
histological type (22). The prognosis for patients with lung cancer is primarily dependent on 
the stage of the tumour at the time of diagnosis. Patients diagnosed early with stage I tumours 
have a 40-70% survival following surgical resection (23). 
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Risk factors for developing lung cancer: 
Smoking remains the leading risk factor and is associated with 90% of cases in women and 
79% in men. Asbestos exposure is the most common occupational risk factor. Other factors 
include exposure to radon, arsenic, chromium, nickel. Pre-existing lung diseases such as 
tuberculosis, Chronic Obstructive Pulmonary Disease (COPD) and idiopathic pulmonary 
fibrosis also increase the risk of developing lung cancer (24).  
Around 10% of lung cancers in asymptomatic patients are detected on chest radiographs, but 
most patients are symptomatic when diagnosed and can present with the nonspecific systemic 
symptoms of fatigue, anorexia, and weight loss (24). Table 1A below shows the treatment of 
lung cancer based on its stage. 
Treatment of Lung Cancer According to Stage 
 
Stage Primary treatment Adjuvant therapy 
Five-year 
survival 
rate (%) 
Non–small cell carcinoma 
I Resection Chemotherapy 60 to 70 
II Resection Chemotherapy with 
or without 
radiotherapy 
40 to 50 
IIIA (resectable) Resection with or without 
preoperative chemotherapy
Chemotherapy with 
or without 
radiotherapy 
15 to 30 
IIIA (unresectable) or IIIB 
(involvement of contralateral 
or supraclavicular lymph 
nodes) 
Chemotherapy with 
concurrent or subsequent 
radiotherapy 
None 10 to 20 
IIIB (pleural effusion) or IV Chemotherapy or resection 
of primary brain metastasis 
and primary T1 tumour 
None 10 to 15 
(two-year 
survival) 
Small cell carcinoma
Limited disease Chemotherapy with 
concurrent radiotherapy 
None 15 to 25 
Extensive disease Chemotherapy None < 5 
 
Table 1A: treatment options for lung cancer by stage (24) 
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Evidence suggests that the Epidermal Growth Factor Receptor (EGFR) is involved in the 
development of various cancers. The EGFR and EGF-like peptides are often over-expressed 
in human carcinomas, and in vivo and in vitro studies have shown that these proteins are able 
to induce cell transformation. Evidence suggests that cooperation of multiple ErbB receptors 
and cognate ligands is necessary to induce cell transformation. In particular, the growth and 
the survival of carcinoma cells appear to be sustained by a network of receptors/ligands of the 
ErbB family. This phenomenon is also important for therapeutic approaches, since the 
response to anti-EGFR agents might depend on the total level of expression of ErbB receptors 
and ligands in tumor cells (25) 
Our gene of interest, Mig-6, has been shown to be a negatiove regulator of EGF signalling so 
we were interested in looking at this pathway and what occurs when Mig-6 is ablated or 
knocked out. 
 
1.2 Mouse Models to study disease development and progression 
The use of mouse models allows us to manipulate various elements of the mouse genome to 
investigate factors involved in disease development and progression in addition to aspects of 
the oncogenic process. It also gives the chance to test potential therapeutic interventions. The 
success of a mouse model is dependent on its ability to target the specific oncogenic 
modification in a cell specific manner. The timing of the genetic modification is also crucial.  
Mouse models are most commonly used to investigate the effect of specific gene ablation on 
the mouse. Two of those in use are conventional knockout models and conditional knockout 
models. Conventional models work on the basis of mutating or ablating endogenous genes by 
using homologous recombination in embryonic stem (ES) cells. Specific genes are targeted in 
vitro and the ES cells with the target modification are injected into 3.5 day old mouse 
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embryos. The ES cells incorporate themselves into the germline and the mutation is then 
transmitted to future generations of mice. The disadvantage of this method is that if the 
mutation introduced affects the ability of the mice to survive, the role of the gene in disease 
development or in the adult mouse cannot be studied.  
Depending on the promoter used to express the transgene, initiation of expression of the 
transgene will be at different times. For example expression of genes under the control of the 
SP-C promoter is initiated at embryonic day 10 while genes under the control of a CCSP 
promoter are initiated at around day 17 of embryonic development. Expression of genes that 
disrupt the different developmental stages results in an embryonic lethal phenotype which 
makes those models of little value when one is interested in following the progression of a 
particular disease or cancer. (7, 8, 9)  
Another limitation in using conventional mouse models is that once transcription of the 
transgene has been initiated it is irreversible. The ability to terminate transgene expression 
would allow identification of the stages of tumour progression independent of the growth 
promoting properties of the transgene. 
As well as the lethal phenotype mentioned above, conventional models may also result in a 
number of non-lethal phenotypes: 
- Artefacts can arise due to the lack of a gene product for the entire lifetime of the 
animal 
- Presence of a selection marker can influence the phenotype of the mutation (26) 
Conditional transgene models have overcome these limitations.  
Conditional knockout models use tissue specific expression of recombinases to ablate genes 
in a cell and tissue specific manner. Site specific recombinases splice DNA segments which 
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are flanked by specific recognisable sequences. Homologous recombination in ES cells is 
used to insert recombinase recognition sequences around a gene of interest or regulatory 
exons. This technology is used to express site specific recombinases in a tissue specific 
manner. This allows the gene of interest, flanked by recombinase sites, to be deleted in a 
tissue specific manner (7, 8, 9, 10).  
Site specific recombinases (SSRs) such as Cre and flp are capable of recombining specific 
sequences of DNA with high fidelity without the need for co-factors and have been used to 
create gene deletions, insertions inversions and exchanges. Both Cre and flp recombine DNA 
at defined target sites and are members of the λ integrase superfamily of SSRs (27). 
Another commonly used recombinase is the PhiC31 phage integrase (a Streptomyces phage) 
(28)  
For the purposes of our experiments we were interested in the Cre-loxP system. 
Cre-loxP system: 
The most common recombinase system in use is the Cre-LoxP system.  
The Cre-lox mechanism was first observed in P1 bacteriophage where it is part of the normal 
viral life cycle allowing replication of its genomic DNA when reproducing.  Since its 
discovery the Cre-lox system has been developed into a technology for genome manipulation 
(29). The site specific recombinase Cre of the bacteriophage PI recognises specifically 34bp 
long sequences called loxP (locus of X over in PI) (30). Cre excises a segment of DNA 
flanked by two loxP sites. Depending on the position and orientation of loxP sites several 
outcomes are possible- gene deletions, duplications, inversions and chromosome 
translocations. Mostly this system is used to conditionally activate or inactivate certain genes 
(31).  
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To be successful, Cre-lox requires only two elements to be present: 
1. Cre Recombinases: catalyses recombination between two loxP sites 
2. loxP sites: 34 base pair sequence containing two 13bp inverted repeats flanking an 
8bp core sequence  
 
Figure 1.3: 34 base loxP sequence. The core sequence (shaded) is flanked by two 
inverted repeats (29)  
This traditional type of Cre-lox system has a number of issues which can make it difficult to 
interpret the knockout phenotype (26): 
1. If a selective marker is present it may have an influence on the phenotype of the 
mutation. 
2. As the gene is knocked out for the lifetime of the transgenic animal, artefacts can 
develop. 
3. Inactivation of some genes can cause lethality in utero which makes it impossible to 
look at the gene’s function later in development or post-natally. 
A variation of the Cre-lox system has found a way to potentially overcome these limitations. 
This version is a conditional gene targeting method based on the inducible activity of an 
engineered DNA recombinase. An inducible system allows control over the timing of the 
recombination event and also allows tissue specific removal of the target gene (26). In these 
inducible forms of Cre, the ligand binding domain of a mutated human oestrogen receptor 
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(ERT) (which recognises Tamoxifen and its derivatives but not normal oestrogen) is fused to 
Cre (31). This Cre-ERT is a functional Tamoxifen-dependent recombinase in cultured cells 
and in transgenic mice (26). By controlling the time point at which the target gene is excised 
using an inducible Cre recombinase, it allows us to look at the role of the gene later in the 
developmental process or in adult life as well as allowing tissue specific excision of the gene 
of interest. Studies have proven the validity of using the Tamoxifen dependent recombinase 
by showing excision of the gene in animals where the drug had been administered but no 
excision in animals that received no Tamoxifen treatment (26).  
1.3 Cell Signalling 
Overview of cell signalling: 
Cell to cell communication in multicellular organisms is essential in order to ensure 
coordination of activities within the organism as a whole (32). Initiation of signal 
transduction occurs when a small molecule known as a ligand binds to its receptor protein 
often causing a conformational change in this receptor protein. Most signal receptors are 
plasma membrane proteins. There are many types of cell membrane receptors (32), three of 
which are listed below: 
1. G-protein coupled receptors (GPCR) 
GPCR contain 7 transmembrane alpha helical domains that bind to extracellular 
ligands via their extracellular domain. This in turn leads to a conformational change in 
their intracellular domain that results in the activation of G proteins in the cytoplasm 
by replacing GDP with GTP. This newly activated protein can then bind to another 
protein, which is usually an enzyme, and initiate the next step in the amplification of 
the signalling pathway. This activation is relatively short lived because the G protein 
contains endogenous GTPase activity that rapidly hydrolyses GTP to form GDP. 
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2. Receptor tyrosine kinases 
These receptors have enzymatic activity within a cell and will be further discussed 
later. 
3. Ion channel receptors 
Ion-Channel Receptors are channel proteins in a plasma membrane that can open or 
close in response to a change in the local concentration of a ligand that binds 
specifically to the ion channel receptor. These channels are usually specific for a 
single ion (e.g. Ca2+ or Cl-) are important in the functioning of the nervous system 
(33). 
Receptor Tyrosine Kinases: 
Receptor tyrosine kinases (RTKs) mediate cell-to-cell communication and are essential 
components of cellular signalling pathways which are active during both embryonic 
development and adult homeostasis. Many RTKs have been implicated in the onset or 
progression of various cancers, either through receptor gain of function mutations or through 
receptor/ligand overexpression (34).  
RTKs are receptors which are found in the plasma membrane and are usually activated by 
ligand induced oligomerisation which juxtaposes the cytoplasmic tyrosine kinase domains. 
This allows autophosphorylation of tyrosine residues which in turn causes a conformational 
change which increases kinase activity (as shown in figure 1.4). Some phosphorylated 
tyrosine residues can attract various different downstream signalling proteins (enzymes and 
adapter proteins), typically through Src-homology-2 (SH2) or phosphotyrosine-binding 
(PTB) domains (34, 35).   
Signal transduction pathways via receptor tyrosine kinases play pivotal roles in numerous 
aspects of physiological and pathological biology. The EGFR family, in particular, has been 
extensively studied as a prototype of RTKs since the 1980s (36). 
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Epidermal Growth Factor Receptor (EGFR): 
EGFR and closely related family members, ErbB2, ErbB3 and ErbB4 are RTKs which send 
signals into the cell to regulate many critical processes (37).  These receptors are at the apex 
of complex signal transduction cascades in a large number of cell types which modulate cell 
proliferation, survival, adhesion, migration and differentiation (38, 39).  
Structure of EGFR 
EGFRs are transmembrane receptors which have an N-terminal extracellular ligand-binding 
domain and a C-terminal cytoplasmic region which has enzymatic activity. This structure 
allows signals to be transmitted across the plasma membrane (39). 
 
Figure 1.4: The above diagram shows a general view of the ligand-induced dimerization 
and activation process of EGFR (40) 
Signalling via EGFR: 
Signalling through the receptor begins when a ligand (EGF, EGF-like molecules, TGF-α and 
neuregulins) binds to the extracellular domain causing a conformational change and the 
signal is transmitted to the intracellular kinase domain. The kinase domain phosphorylates 
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several tyrosine residues in the C-terminal tail of the receptor which recruits PTB and SH2 
domains containing signalling proteins and relays the signal to downstream signalling 
pathways (37) 
 
Figure 1.5: The epidermal growth factor receptor (EGFR) signal transduction model. 
Ligand binding to receptors on the cell surface induces receptor dimerisation and cross 
phosphorylation. A transient signalling complex composed of effector and adaptor proteins is 
then assembled. Dissociation of this complex leads to an enzymatic cascade culminating in 
gene activation and a cellular response. During signal termination, ligand–receptor complexes 
are internalised through clatherin-coated regions of the plasma membrane and then either 
degraded or recycled to the cell surface (39). 
EGF signalling is important in early and late stage lung development and its ablation leads to 
reduced lung branching and alterations in epithelial cell population (41). EGF can also 
activate downstream signalling, Ras-PI3K/Akt and Ras/MAPK and cross-talk with other 
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growth factors such as TGF-β1 and HGF signalling which are all important in lung 
development (5).  
 
Feedback inhibition of EGFR signalling: 
Signalling networks need to be coordinated in a strictly controlled manner and negative 
regulators have been shown to have an important role in this regulation. Continuing research 
has shown that a number of negative regulators exist which play major roles in regulating 
signalling networks via multiple modes of action. The coordinated action of positive and 
negative regulators provides the fine tuning necessary to maintain correct signalling pathways 
(42). It has been seen that loss or decrease in expression of negative regulators can be linked 
to cancer development (36).  
Negative regulators of EGFR signalling include the following: 
- Mitogen inducible gene 6 (Mig-6)/RALT/Gene 33 (43) 
o This is an early-response gene induced by EGF. Its transcription is induced by 
the extracellular signal-regulated kinase (ERK) pathway that is activated by 
growth factors such as EGF or by multiple stimuli, including osmotic and 
mechanical stress. Mig-6/RALT/Gene 33 binds to the tyrosine kinase (TK) 
domains of EGFR and ErbB2 and inhibits TK activity. 
o Studies of the crystal structures that form between Mig-6 and the kinase 
domain of EGFR have shown that an approximately 25 residue epitope of 
Mig-6, known as segment one, binds to the distal surface of the C lobe of the 
kinase domain. Other analyses (biochemical and cell based studies) confirm 
that this interaction, seen on examination of the crystal structures, contributes 
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to EGFR inhibition by blocking the formation of the activating dimer 
interface. (44, 45) 
 
 
- Fibroblast growth factor receptor substrate 2 beta (FRS2β) 
o FRS2β constitutively binds to EGFR, regardless of ligand stimulation. After 
activation of ERK by various growth factors, including EGF, the 
phosphorylated ERK binds to FRS2β and inhibits EGFR autophosphorylation 
and signal transduction. Thus, FRS2β acts as a negative feedback regulator of 
EGFR (46). 
- Suppressor of cytokine signalling 3 (SOCS3)/SOCS4/SOCS5 
o Is an early-response gene induced by EGF. SOCS proteins are negative 
feedback regulators of EGFR. They bind to autophosphorylated EGFR via 
their SH2 domains and recruit E3 ubiquitin ligase complex via their SOCS 
domains, leading to the ubiquitinylation and degradation of EGFR(47). 
-  Leucine-rich repeats and immunoglobulin-like domains 1(LRIG1) 
o  An early-response gene induced by EGF. LRIG1 acts as a negative feedback 
regulator of EGFR (48). It binds to EGFR via its extracellular domain and 
recruits Cbl – an E3 ubiquitin ligase – via its cytoplasmic domain, leading to 
the ubiquitinylation and degradation of EGFR (36). 
The modes of action of these inhibitors are shown in figure 1.6 below 
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Figure 1.6:  Multiple modes of action of the inhibitors. (A) Mig-6/RALT transcription is 
induced by the activation of ERK pathway via activated EGFRor other stimuli. The translated Mig-
6/RALT binds to the activated TK domain of EGFR and ErbB2 and inhibits the TK activity. (B) 
FRS2β constitutively binds to EGFR. Activated EGFR or other stimuli activate the ERK pathway. 
The activated ERK binds to FRS2β and inhibits the EGFR signalling. (C) SOCS3, SOCS4, or SOCS5 
transcription is induced by stimulation with EGF. The translated SOCS3/SOCS4/SOCS5 binds to the 
autophosphorylated EGFR via its SH2 domain and recruits the E3 ubiquitin ligase complex via its 
SOCS box. (D) LRIG1 transcription is induced by stimulation with EGF. The translated LRIG1 binds 
to EGFR family members via its extracellular domain and recruits Cbl E3 ubiquitin ligase to its 
cytoplasmic tail, inducing ubiquitinylation/degradation of the EGFR family members (36) 
HGF signalling: 
Hepatocyte growth factor/scatter factor (HGF) is a multifunctional factor produced by many 
cell types, including normal fibroblasts, epithelial and endothelial cells, but also different 
oncogenic cells. 
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Mesenchymal-epithelial tissue interactions are important for development of various organs, 
and in many cases, soluble signalling molecules may be involved in this interaction. 
Hepatocyte growth factor (HGF) is a mesenchyme-derived factor which has mitogenic, 
motogenic and morphogenic activities on various types of epithelial cells and is considered to 
be a possible mediator of epithelial-mesenchymal interaction during organogenesis and organ 
regeneration. It has been suggested that HGF is a putative candidate for a mesenchyme-
derived morphogen regulating lung organogenesis (49). 
 
 HGF has been reported to influence cell proliferation of hepatocytes and multiple other cell 
types, kidney cell migration, organ and tissue development, but also the invasiveness of 
tumour cells and other biological responses (50, 51). HGF binds to the receptor tyrosine 
kinase c-Met which transmits the HGF signal into the cytoplasm (52). c-Met 
autophosphorylation leads to the recruitment of signal transduction proteins like the c-Src 
kinase, phospholipase C-g, the Grb2zSoS complex, and phosphatidylinositol 3-kinase (51).  
 
The mature HGF protein binds to its high-affinity receptor c-MET, leading to its activation 
and phosphorylation of multiple serine and tyrosine residue sites. The extracellular Sema 
domain of c-MET mediates binding to the ligand HGF, which, subsequently, leads to receptor 
dimerisation and activation of its intrinsic tyrosine kinase. The c-MET/HGF pathway has 
gained considerable interest through its apparent deregulation by overexpression or gain-of-
function mutations in c-MET in various cancers, including lung cancer (53, 54). The figure 
below (1.7) illustrates the interaction of HGF and c-MET and the resulting pathways which 
are stimulated (54). 
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Figure 1.7: shows the versatile signalling functions of c-MET/HGF pathway regulating 
various biological functions of the cells, including cytoskeletal functions, cell proliferation 
and differentiation, survival, and apoptosis. Various potential serine, threonine and tyrosine 
phosphorylation sites on the signalling phosphoprotein intermediates are included (54).  
The ability of HGF to stimulate mitogenesis, cell motility and matrix invasion means it has a 
central role in angiogenesis, tumourogenesis and tissue regeneration (51). There is evidence 
that HGF plays an essential part in parenchymal repair and protection in various organs. In 
the lungs, HGF is a potent regenerative and cytoprotective factor during organogenesis or in 
cases of acute injuries (55). c-MET is normally expressed by epithelial cells but is also found 
on endothelial cells, neurons, hepatocytes, haematopoietic cells and melanocytes. HGF 
expression is restricted to cells of mesenchymal origin (49, 56).  
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1.4 Mig-6 
Mig-6 is an immediate early response gene (& adapter protein) that is transcriptionally 
induced by a divergent array of extracellular stimuli including various growth factors, 
cytokines and stress factors  as well as by the Ras oncoprotein (1, 2, 3). Mig-6 is also known 
as receptor associated late transducer (RALT), gene 33 (in rat) and ERBB feedback inhibitor 
1 (ERFFI1) (2).  Mig-6 has been mapped to human chromosome 1p36 and to the distal region 
of mouse chromosome 4 (4). The Mig-6 gene spans ~13.8kb and contains four exons 
including the non-coding exon 1 and the coding exons 2-4. The Mig-6 full length transcript is 
3.1kb and encodes a protein of 461 amino acids (6). 
At least five functional regions have been identified in the Mig-6 gene which are: 
1. Threonine/serine phosphorylation region 
2. Src-homology 3 (SH3) binding domain 
3. Cdc42/Rac interaction and binding (CRIB) domain  
4. 14-3-3 binding domain  
5. ErbB-2 binding domain (5) 
The Mig-6 gene has a number of features including the following: it is present only in higher 
animals such as humans and rodents but not in lower ones like Drosophila or C.elegans. This 
suggests that Mig-6 was acquired during evolution for regulating more complex signalling 
networks. Secondly, since it is an immediate early response gene its expression can be rapidly 
induced, it may play an important role in early regulation of cellular responses (4).  
Transcriptional regulation of Mig-6: 
Mig-6 expression can be induced by a wide variety of external stimuli, a summary of some of 
which are listed in table 1B below 
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Transcriptional inducers of Mig-6 expression 
Growth Factors Stresses Hormones/Others 
EGF Diabetic nephropathy Glucocorticoids 
FGF Hypoxia Insulin 
HGF Live Staphylococcus infection Retinoic acid 
TGF-α Ventilator induced lung injury Alklyating agents 
PDGF Mechanical strain cAMP 
 
Table 1B: Summary of the transcriptional inducers of Mig-6 expression (4) 
Various inducers can differentially activate the regulation of Mig-6 and may use different 
intracellular pathways to accomplish this regulation. The induction of Mig-6 by growth 
factors such as EGF is mediated via the Ras-MEK-ERK pathway. The MEK-ERK pathway is 
also responsible for Mig-6 induction by serum, phorbol and sorbitol induced osmotic stress. 
Regulation of insulin induced Mig-6 expression varies in different cell types. The PI-3K and 
ERK pathways are involved in hypoxia induced Mig-6 expression (4). 
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Figure 1.8 shows the known and potential actions of Mig-6 on the EGF, HGF/SF and certain 
stress induced signal transduction. 
Mig-6 in development, homeostasis and stress response: 
Mig-6 expression levels differ among different tissues and also in the same tissues at different 
time points during foetal development and adult maturation. The mouse liver contains high 
levels of Mig-6 while varied levels are present in the lung, placenta, heart, brain, stomach and 
skeletal muscle. The foetal liver shows low levels of Mig-6 expression while a sharp increase 
is observed in the newborn liver (this suggests that, at birth, the hepatocytes respond to 
hormonal  and/or environmental changes) (4). The level of Mig-6 expression in the lung 
differs throughout the gestational period as can be seen in Figure 1.9 below: 
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Figure 1.9: Differential expression of Mig-6 during murine lung development. (A) Mig-6 
relative mRNA levels in E13.5, E14.5, E15.5, E16.5, E17.5, E18.5, P1, P3, P4, P5, P10, and 
adult (3-month-old, AD) lungs by quantitative real-time RT-PCR. (5)  
E13.5→E18.5: embryonic day 13.5-day 18.5. P1→P10: pups day 1→10. 
In mice, genomic disruption of the mig-6 gene leads to degenerative joint diseases, skin 
cancer, lung cancer and gastrointestinal tract tumours. It has been demonstrated that ablation 
of Mig-6 results in a partial lethal phenotype with 50% of these mice dying during the 
neonatal period (5).   
Mig-6 is a negative regulator of EGF signalling 
Mig-6 can be transcriptionally induced by EGF, and it acts as a negative feedback inhibitor of 
EGF receptor signalling by blocking formation of the activating dimer interface (44). Mig-6 
interacts with the EGFR in vivo in an EGF-inducible manner (58). Overexpression of Mig-6 
in vitro leads to inhibition of ErbB2 autophosphorylation and reduced MAPK pathway 
activity, through binding of Mig-6 to ErbB receptors (2).  
 The C-terminal region of Mig-6 contains a segment (residues 323-372) which is essential for 
EGFR and ErbB2 binding. Studies of the crystal structure of the area around this segment has 
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defined a 25-residue epitope of Mig-6 that binds to the EGFR (ErbB2) kinase domain and has 
been given the term segment 1. The footprint of Mig-6 (segment 1) on the kinase domain of 
EGFR overlaps the cyclin-like face of the kinase domain in the asymmetric kinase domain 
dimer, and so binding of Mig-6 to an EGFR kinase domain will prevent it from acting as a 
cyclin-like activator for other kinase domains. Residues in the Mig-6 binding interface of 
EGFR are conserved suggesting that Mig-6 could potentially bind to other members of the 
EGFR family. Introduction of individual mutations in Mig-6 (segment 1) interrupts the 
binding of EGFR and Mig-6, proving that it is segment 1 which is important for inhibition of 
EGFR. An interesting property of Mig-6 is its ability to bind more tightly to activated EGFR 
than to the unbound receptor (44).  
Mig-6 as a tumour suppressor gene 
Mig-6 localises in human chromosome 1p36, a locus that has been widely suggested to 
harbour putative tumour suppressor genes including EXTL1 (a candidate neuroblastoma 
suppressor gene) as well as p73, the p53 tumour suppressor gene homolog. No mutations in 
p73 have been identified in human lung cancer so it can be discarded the responsible tumour 
suppressor in the lung. Allelic imbalance of chromosome 1p36 is one of the most frequent 
genetic alterations observed in various human cancers (3).   
 It is plausible to consider Mig-6 as a potential tumour suppressor gene for many different 
reasons, some of which are listed below: 
- It is located on chromosome 1p36.12-36.33, a locus considered a hot spot of allelic 
imbalance for lung cancer (3) 
- Loss of function mutations in Mig-6 have been identified in human lung cancer cell 
lines 
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- It is negative regulator of receptor tyrosine kinase signalling from EGF and HGF, 
whose receptors have been shown to play important roles in lung malignancy (3) 
Mig-6 knock-out models have been developed in order to further study the role of Mig-6 in 
different organs both during foetal development and after birth into adulthood. One such 
model has been generated in the DeMayo laboratory at Baylor College of Medicine. The 
embryo lethal phenotype and multi-tissue carcinogenesis of the Mig-6 null allele make it 
difficult to investigate the impact of ablation of Mig-6 on specific tissue and at specific time 
points in development. In order to look at the role of Mig-6 in specific tissues, a conditional 
knock out model would be useful. The DeMayo lab have successfully generated a conditional 
null allele, Mig-6f/f, by introducing LoxP sites that flank exons 2 and 4 of the Mig-6 gene.  
The Mig-6 conditional null allele was validated in the recombined Mig-6-/- mice by 
measuring Mig-6 mRNA and protein in the liver, lung, uterus and skin. Neither mRNA nor 
protein of Mig-6 could be detected by real time RT-PCR or Western blot analysis in the liver, 
lung, uterus and skin of recombined Mig-6-/- mice (34).The recombined Mig-6-/- mice 
developed pathological changes such as degenerative joint diseases and skin hyperplasia, 
similar to the previously reported Mig-6 germline null allele. These mice also had enlarged 
uteri with endometrial hyperplasia. This Mig-6f/f mouse is used as a valuable tool in the study 
of Mig-6 in a tissue specific manner (6).  
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Aims: 
We approached our work with two main aims which were to use animal studies and cell 
studies to look at the role of Mig-6.  
In our animal studies we planned to use the previously mentioned conditional knockout 
model to look at what occurs in murine lungs when Mig-6 is ablated. We would analyse our 
results using quantitative real time pcr and Western blot analysis.  
The cell studies would focus on epithelial and endothelial cells. We aimed to knockdown 
Mig-6 expression in these cells using siRNA to determine what effects (if any) this would 
have on cellular survival and also what pathways may be involved in response. We would 
also look at EGF stimulation studies in both cell types. Again we would look at our results 
using real time pcr and Western blot analysis.  
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2. Materials and Methods 
Animal strains used: 
We used the Mig-6f/f mice in order to study the role of Mig-6 in adult mice by developing an 
inducible ablation model which produced our Mig-6d/d mice. To obtain our Mig-6d/d mice, 
Rosa26-Cre-ERT2 mice were crossed with Mig-6flox/flox mice and the resulting Rosa26-Cre-
ERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6flox/flox (Mig-6f/f) mice (2 months old) were 
injected peritoneally with 1 mg of Tamoxifen for 5 days. These mice were further maintained 
for 4 months before analysis. It was expected that in the Mig-6d/d mice Mig-6 would have 
been successfully ablated. At six months old mice were sacrificed, lung tissue harvested and 
our experiments carried out.  
 
2.1: siRNA treatment of epithelial and endothelial cells 
Materials 
- siRNA (Thermo Scientific, Dharmacon)- ON-TARGET plus SMART pool human 
Mig-6 
- Penicillin/Streptomycin (100X) (GIBCO) 
- Lipofectamine 2000 reagent (Invitrogen) 
- Opti-MEM (Invitrogen) 
- Culture Plates (Grenier labortechnik) 
- RPMI 1640 (Invitrogen) 
- FBS (Invitrogen) 
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2.1 siRNA treatment of epithelial and endothelial cells 
siRNA treatment was carried out on these epithelial and endothelial cells in order to knock 
down Mig-6 and investigate the effect (if any) this would have on genes downstream from 
Mig-6 in signalling pathways. We were also interested to see whether knocking down Mig-6 
would affect cell viability. Protein and RNA were isolated from the treated cells for Western 
blot and real time PCR analysis.  
The H441 human bronchiolar epithelial cells (National Cancer Institute, Frederick, MD) were 
grown in RPMI 1640 (+ 10% FBS + P/S (penicillin/streptomycin)) until 40% confluency. 
Human lung micro vascular endothelial cells (HMVEC-L, Lonza, Walkersville, MD) were 
maintained in Endothelial Cell Medium containing hEGF, hydrocortisone, GA-1000, FBS, 
VEGF, hFGF-B, R3-IGF-1, and ascorbic acid (Bullet Kit, Lonza) until 60% confluency. 
Cells were cultured in the Tissue Culture Core (TCC) at Baylor College of Medicine. Culture 
medium was RPMI 1640 medium supplemented with 2 mM L-glutamine, 1.5 g/l sodium 
bicarbonate, 4.5 g/l glucose, 10mM HEPES (pH 7.4), 10% foetal bovine serum, and 1%v/v 
antibiotics to prevent bacterial growth. Cells were cultured at 37oC in 5% CO2 and passaged 
every 3 days.  
Cells were transfected with 50 nM of control siRNA or SMART pool of human Mig-6 
siRNA (Dharmacon, Chicago, IL) in serum-free OptiMEM (Invitrogen, Carlsbad, CA).  
For each 6 well culture plate the following steps are carried out.  
33µl of lipofectamine with 660µl of opti-MEM is mixed (by pipetting ~50 times) and left to 
settle for 30mins. To each of six microtubes 100µl of opti-MEM was added along with the 
volume of siRNA required to give a final concentration of 50nM. 100µl of opti-MEM 
containing lipofectamine was added to the opti-MEM containing siRNA mixed by pipetting 
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approx. 50 times and left to settle again for 30 min. A tube containing opti-MEM,  2% FBS, 
and 1%v/v antibiotics was prepared.800µl of opti-MEM containing 1x antibiotics plus 2% 
FBS was added to the lipofectamine siRNA mixture. 1000µl of opti-MEM with 2% FBS, 
lipofectamine and siRNA mixture was added to each well. After overnight culture, 1 ml of 
RPMI 1640 medium containing 20% FBS and 1% antibiotics was to each well and culture 
continued for a further 48hrs. Following culture, protein and RNA were isolated from the 
cells for Western blot and real time PCR analysis.  
2.2 EGF/HGF induction of Mig-6 in siRNA treated cells  
Materials 
- 40ng/ml EGF 
- 40ng/ml HGF 
- BEBM (bronchial epithelial cell basal medium) (Lonza) 
- Protein Lysis Buffer (10 mM Tris HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 0.1% NP40, 1 
mM PMSF, 10 µg/ml aprotonin, and 10 µg/ml leupeptin)- Sterile PBS pH7.4- Cell Star 
macroplate with lid (Grenier labortechnik) 
- opti-MEM (GIBCO) 
2.2 EGF/HGF induction of Mig-6 in siRNA treated cells  
NHBE (normal human bronchial epithelial) cells were cultured (in BEBM) and subjected to 
siRNA treatment to knock down Mig-6 as detailed for the H441 and HMVEC cells in section 
2.1.  The siRNA treated cells in culture at ~50% confluency were then subjected to treatment 
with 40ng/ml of EGF (epidermal growth factor) and HGF (hepatocyte growth factor) (24hrs 
post siRNA treatment)  to investigate what effect, if any, addition of these substances would 
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have on Mig-6 and other protein levels. siRNA silences Mig-6 expression but it was 
hypothesised that addition of either EGF or HGF could induce expression of Mig-6 once 
again and levels would increase post administration of the growth factors. 
Stock solutions of EGF (100μg/ml) and HGF (10μg/ml) were firstly diluted to a 
concentration of 40ng/ml in opti-MEM medium. After siRNA treatment was complete 
(72hrs), the media was removed from each culture well, rinsed with opti-MEM and 1ml of 
either EGF 40ng/ml or HGF 40 ng/ml was added. Culture plates were incubated at 37oC with 
5% CO2 for 0mins, 15mins, 30mins, 1 hr, 2hrs and 4hrs. At each of the above time points the 
treated cells were harvested for protein.  
2.3 SDS PAGE and Western blot 
Materials:  
‐ Protein marker- Precision Plus Protein Standards (BIO-RAD) 
‐ Gel: 
o BIO-RAD ready gel, precast gel for electrophoresis (BIO-RAD) 
‐ Mini-Trans Blot Electrophoretic Transfer Cell (BIO-RAD)Gel transfer cell, gel holder 
cassettes, fibre pads, electrodes, tank, cooling unit, lid with cables 
‐ Milk- Nestle Carnation instant non fat dry milk powder 
‐ Weighing scales TR 603D, (Denver Instrument Company) 
‐ X-Ray film- HyBlot Cl Premium autoradiography film (Denville Scientific Inc.) 
‐ Autoradiography Cassette (Fisher Scientific) 
‐ RestoreTM Western blot Stripping Buffer (Thermo Scientific)  
‐ AmershamTM ECL Plus Western blotting detection system (GE Healthcare) 
‐ PVDF  Membrane (0.45µm), Immobilon-P transfer membrane (Millipore) 
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‐ Gel Filter Paper (Whatman) 
‐ PBS: 
o 1LH2O 
o 8g NaCl (Sigma) 
o 80ml Phosphate buffer pH 7.4 (Sigma) 
‐ PBST (Wash Buffer) 
o 1L PBS 
o 20µl 20%Tween 20 (Fisher Scientific) 
‐ Blocking Buffer: 
o 100ml PBST 
o 1g non-fat dry milk (Nestle) 
 
‐ 10x TBS 
o 200ml 1M Tris-HCl (pH 7.5) 
o 300ml 5M NaCl 
o 500ml H2O 
‐ Alternative wash buffer (TBST) 
o 1x TBS with 0.1% Tween-20 
‐ Alternative blocking buffer 
o 100ml 1x TBST 
o 5g non-fat dry milk (Nestle) 
‐ 5X running buffer: 
o 15.1g Tris  
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o 94g glycine 
o 50ml 10% SDS 
o Make up to 1000ml with water 
‐ 1x transfer buffer: 
o 2.9g glycine 
o 2.8g Tris 
o 200ml methanol 
o Adjust to 1000ml with water 
Primary antibodies: 
‐ Anti- Met, rabbit polyclonal (Santa Cruz Biotechnology) 
‐ Anti-EGFR, rabbit polyclonal (Santa Cruz Biotechnology) 
‐ Anti- Akt, Mouse monoclonal (Santa Cruz Biotechnology) 
‐ Anti- p-Akt (Ser 473), rabbit polyclonal (Santa Cruz Biotechnology) 
‐ Anti-RALT/MIG-6 (PE-16), rabbit polyclonal (Sigma Aldrich) 
‐ Anti- Actin, mouse monoclonal  ( clone AC-40) (Sigma Aldrich) 
Secondary antibodies: 
‐ Peroxidase labelled rabbit anti-mouse IgG (Santa Cruz Biotechnology) 
‐ Peroxidase labelled goat anti-rabbit IgG (Santa Cruz Biotechnology)  
- Protein lysis buffer 
o (10 mM Tris HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 0.1% NP40, 1 mM 
PMSF, 10 µg/ml aprotonin, and 10 µg/ml leupeptin) 
- Eppendorf tubes 
- Heating block (Fisher Scientific) 
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- Parafilm 
2.3 SDS PAGE and Western blot 
Protein Isolation from siRNA treated cells: 
To harvest the proteins the following was carried out: media was removed from the 
appropriate well and 100μl of protein lysis buffer added. A pipette tip was used to scrape the 
bottom of the culture well to remove all cells and ensure complete homogenisation. The cell 
lysates were transferred to labelled eppendorf tubes, covered with parafilm and boiled for 5 
mins to inactivate endogenous enzyme activity such as phosphatase activity.  
In the case of our time course studies 100μl of PBS (pH7.4) was added to the resulting empty 
culture well and the remaining cells in the culture plate placed back in the 37oC incubator 
until the next time point for protein harvesting. In all cases the amount of protein harvested 
was measured to allow us to adjust our loading to ensure equal protein amounts were loaded 
onto the gel. The lysates could be immediately used for Western blot analysis or frozen at -
20oC for future analysis.   
Western blot was used to analyse the protein samples collected from H441 epithelial cells, 
HMVEC cells and NHBE cells. We wanted to look at the effect knocking down Mig-6 had 
on Akt, p-Akt, mTor, p-mTor, c-Met, EGFR and p-EGFR levels in our cells..  
The running apparatus was prepared and the gel inserted into the cassette and the comb 
removed. The cassette was placed into the tank and 1x running buffer poured in until all wells 
were fully submerged. 5µl of protein marker was added to well number one. 20µl of sample 
was added to the remaining wells. The apparatus was connected to a power supply and run at 
a constant voltage of 100V for approximately two hours. Once the dye front had run approx. 
2/3 of the length of the gel the protein was transferred to a PVDF membrane as follows: one 
edge of the membrane was labelled and the entire membrane was then submerged in 
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methanol. The transfer apparatus was assembled (Black side of cassette down, sponge, filter 
paper, gel, membrane, filter paper, sponge), ensuring there were no air bubbles between 
layers to hinder an efficient transfer. Once assembled, the transfer apparatus was placed into 
the tank. An ice pack was placed in the tank and transfer buffer poured in until the cassette 
containing the gel and PVDF membrane was completely covered. This was run at 50-60V for 
two hours.  
Blocking Step: 
Following the transfer step, the membrane was rinsed briefly with PBS. This was followed by 
blocking in blocking/staining solution for one hour at room temperature on a plate rocker. 
Primary antibody: 
Antibodies were diluted as required- 1:1000 in blocking/staining solution. Following the 
blocking step, the diluted primary antibodies were applied to the membrane (10ml per 
membrane). Primary antibody was incubated at 4oC overnight on a plate rocker.  
Washing step: 
The following day the membrane was washed with PBST for ten minutes at room 
temperature on a plate rocker. This wash solution was discarded and the wash step was 
repeated twice to ensure sufficient washing was achieved.  
Secondary Antibody 
Following the wash step, enzyme-conjugated secondary antibody raised against the primary 
antibody was applied (at a dilution of 1:1000). Secondary antibody incubation was for one 
hour at room temperature on the plate rocker. Following secondary antibody incubation, the 
membrane was washed again as detailed above. 
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ECL treatment: 
In order to be able to visualise the protein bands, lumigen must be applied to the membrane. 
For each membrane ~1ml of lumigen is required. 1ml of lumigen A (GE Healthcare ECL 
Plus Western blotting detection system) was mixed with 25µl of lumigen B. The lumigen 
mixture was applied to the membrane and incubated for two to three minutes. The membrane 
was then transferred to an autoradiography cassette.  
In the dark room an autoradiograph film was placed on top of the membranes. Initial 
exposure time was ten mins and then reduced or increased depending on the result seen upon 
development of the first film.  Films were developed by placing the exposed film into the 
processor and protein banding patterns were observed. Digital copies of the negatives were 
taken using a Sony 10 mega pixel camera and a white light box to back-illuminate the film.  
Stripping the membrane for re-use: 
In order to re-use the membrane and apply a new set of antibodies all primary and secondary 
antibodies bound to antigen on the membrane needed to be first stripped from the membrane. 
To do this we used a commercial stripping buffer (containing beta-mercaptoethanol) which 
strips off the primary and secondary antibodies while leaving the protein sample on the 
PVDF membrane. Approximately 5ml of stripping buffer was applied to the membrane and 
incubated for 15mins on the plate rocker at room temperature. Following stripping, the 
membrane was rinsed with PBS and blocked with 1% milk for 1 hour at room temperature 
followed by the new primary antibody for one hour at room temperature. From this point on 
the procedure was followed exactly as detailed above. 
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Western blot- alternative procedure: 
We began having difficulties with some of our Western blot results so we decided to optimize 
the method to enable us to get better, more reproducible results. These changes will be 
detailed here and referred to in the relevant results section: 
Changes were made to the buffers and blocking solution used. Instead of using PBST we 
switched to TBST (Tris buffered saline & 0.1% Tween) for our washing steps and also for 
making our blocking solution. Instead of blocking with 1% milk in PBST for one hour we 
instead just briefly rinsed the membrane with 5% milk in TBST. Antibodies were diluted in 
5% dry milk powder (w/v) in TBST instead of 1% dry milk powder (w/v) in PBST. For each 
wash step we reduced the length of time from ten minutes to eight.  
2.4 RNA Isolation 
Materials: 
‐ TRIzol® reagent (Invitrogen) 
‐ Chloroform (Fisher Scientific) 
‐ Isopropanol (Fisher Scientific) 
‐ 70% ethanol (PHARMACO-AAPER) 
‐ Microcentrifuge tubes 
‐ Pipettes -P1000, P200, P20 (Gilson) 
‐ Centrifuge 
‐  UV  spectrometer 
‐ TipOne pipette tips (USA scientific Inc.) 
‐ DEPC treated water 
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2.4 RNA Isolation 
RNA was isolated from siRNA treated cells and also from frozen mouse lung tissues. The 
RNA was used for real time PCR analysis. 
Prior to RNA Isolation from samples, the bench area, pipettes, other instruments and gloves 
were sprayed with 70% ethanol to avoid RNase contamination and maximise the amount of 
RNA isolated from the samples. All dilutions were made using DEPC treated water.  
Cultured cells were lysed directly in the culture dish by adding 1ml of TRIzol® reagent to a 
3.5cm diameter dish, and the cell lysate was passed through a pipette several times. The 
homogenised samples were incubated at room temperature for five minutes to allow complete 
dissociation of nucleoprotein complexes. 0.2ml of chloroform (Fisher Scientific) was added, 
sample tubes capped securely and tubes shaken vigorously (by hand) for ~15 seconds. 
Samples were incubated at room temperature for two to three minutes and then centrifuged at 
12,000 x g for 15 minutes at 4oC. Following centrifugation the sample separated into a lower 
red phenol–chloroform phase, an interphase and a colourless upper aqueous phase 
(containing the RNA). The aqueous phase was transferred to a fresh tube and RNA 
precipitated by addition of 0.5ml isopropyl alcohol (Fisher Scientific). Samples were 
incubated at room temperature for ten minutes to precipitate RNA and then centrifuged at 
12,000x g for ten minutes at 4oC. After centrifugation the RNA forms a gel-like pellet on the 
side and bottom of the tube. The supernatant was removed and the RNA pellet washed with 
1ml 70% Ethanol (PHARMCO-AAPER). Sample was mixed by vortexing (Fisher 
Scientific) and then centrifuged at 7,500 x g for five minutes at 4oC. After ethanol wash, the 
pellet was briefly dried by vacuum. RNA was dissolved in 30µl DEPC 
(Diethylpyrocarbonate) water. RNA was then quantified by UV spectrometry. An aliquot of 
each sample was diluted 1 in 65 with a final volume of 260µl (4µl RNA in 260µl water) 
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RNA was isolated from frozen lung tissue in essentially the same manner as for cells, with 
the following exception. When isolating RNA from the tissue samples, after addition of 
TRIzol® reagent (per lung) the tissues were homogenised and placed on ice until all samples 
had been homogenised. From this point, the procedure was the same as for the cultured cells. 
2.5 Quantitative Real Time PCR  
Materials: 
‐ 5x first strand buffer (Invitrogen) 
‐ 0.1M DTT (Invitrogen) 
‐ Ribonuclease inhibitor, Cloned (Invitrogen) 
‐ Hexamer (random primer) (Invitrogen) 
‐ MMLV- reverse transcriptase (Invitrogen) 
‐ 10mM dNTPs 
‐ PCR tubes (Fisher Scientific) 
‐ iTaq SYBR® Green (BIO-RAD) 
‐ 96 well optical reaction plate with barcode (ABI PRISM,  Applied Biosystems) 
‐ MicroAmp™ Optical adhesive film (Applied Biosystems) 
2.5 Quantitative Real Time PCR 
Quantitative real time PCR was employed to investigate if a successful knock down of Mig-6 
had been achieved in our epithelial and endothelial cells and to quantitate expression of a 
number of molecular markers in mouse lung tissue. 
2.5.i: Reverse Transcriptase PCR (RT-PCR) 
Firstly the following was mixed in a tube: 2µg RNA sample, 1µl dNTP, 1µl random primer, 
water to a volume of 12µl. This mixture was heated to 65oC for five minutes and then quick 
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chilled on ice. The following mixture was prepared and added to the RNA/dNTP/random 
primer mix: 4µl 5x first strand buffer, 2µl DTT, 0.5µl RNase inhibitor, 1µl MMLV reverse 
transcriptase, 0.5µl water. The RT-PCR mix was put on a thermocycler (MJ Research) and 
the following conditions programmed: 25oC 10 mins, 37oC 50 mins, 70oC 15 mins.  
This cDNA was stored at -20oC until its use as the template for quantitative real time PCR. 
2.5.ii: Quantitative Real-time PCR 
Quantitative real-time PCR was performed by using Taqman probe or SYBR Green master 
mix (Applied Biosystems, Foster City, CA) to quantitate the expression levels of Mig-6, 
surfactant associated protein C (SP-C), T1 , and mucin 5 subtypes A and C (MUC5AC), in 
the Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d  mouse lungs. Primers and probe sequences are 
listed in Table 2.1.  
cDNA samples were diluted 1 in 5 in DEPC water for Mig-6, SP-C, T1 α and MUC5AC and 
a further 1 in 500 for the 18S samples (This follows a protocol already in use in our lab). 
Once samples were diluted appropriately the following mixtures were prepared for each 
marker being investigated: cDNA 5μl, master mix (containing taq, forward and reverse 
primers, MgCl2 and dNTPS) 1μl, H2O 6.5μl. Reactions were prepared in 96 well optical 
reaction plates (Applied Biosystems) and the plates sealed with adhesive film to prevent 
evaporation during the reaction. Thermal conditions for the reaction were as follows: 50oC 
2mins followed by 40 cycles of 95oC for 15seconds and 60oC for 1 minute. Data was 
collected at each 60oC point in the reaction. Levels for each target marker were compared for 
samples from Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice. 
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Table 2.1: Primer sequences for real-time PCRa 
SP-C Forward: 5'-ACGACGACCACGAATTCCTG-3' 
Reverse: 5'-CCTCCCAACTACATGGTGGTG-3' 
T1 Forward: 5'-TCAAAGCATCTGCCTTTGGAA-3' 
Reverse: 5'-ACTGTCTTGGCTTTGCTCCATT-3' 
MUC-5ACb Forward: 5'- AGAATATCTTTCAGGACCCCTGCT -3' 
Reverse: 5'- ACACCAGTGCTGAGCATACTTTT -3' 
Probe: 5'- CTCAGCGTGGAGAATG -3' 
 
a Taqman primers and probes from Applied Biosystem (Foster City, CA) were used for 
quantification of gene Mig-6, CC10, and 18S rRNA and the sequences are not listed as they 
are not available  
b Primers and probe of MUC-5AC were kindly provided by Dr. Christopher M. Evans from 
University of Texas, M.D. Anderson Cancer Centre. 
2.6: Measurement of Alveolar Spaces: 
Materials 
- Images of H&E stained tissues taken at 40x magnification 
- Grid 
- Ruler 
The size of alveolar spaces were measured on sections taken from wild type, Mig-6 knock 
out, f/f and d/d mice in order to assess whether any difference in size is seen in the different 
mice. It has previously been seen in our lab that Mig-6 knockout mice have larger alveolar 
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spaces than wild type mice so we wanted to see if the same was true in our induced knockout 
mice.  
Measurements were performed on wild type, Mig-6 knock out, f/f and d/d mice. The size of 
the alveolar airspace was determined by measuring mean chord lengths on H&E-stained lung 
sections (59). Images were taken at 40x from five representative, non-overlapping fields of 
lung from at least 8 mice. A grid consisting of 6 black lines at 35-μm intervals (scale) was 
overlaid on the image. Areas of bronchiolar airways and blood vessels were eliminated from 
the analysis. The length of lines overlapping the alveoli was measured and averaged giving 
the mean chord length of the alveolar space. All quantitative studies were performed blind 
with regard to animal genotype and were repeated by a second person to ensure no bias. 
2.7: MTT Assay 
Materials: 
-  dye solution (Promega) 
- Solubilisation/stop solution (Promega) 
- N,N-dimethylformamide 
- Sodium dodecyl sulphate 
- Acetic acid 
- UV  spectrometer 
- Cell titre plate 
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2.7 MTT Assay 
We carried out MTT assays on our siRNA treated H441 and HMVEC cells to see if the 
knock down of Mig-6 had any effect on cell viability.  
The MTT assay is a cell viability assay in which cell permeable MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), usually a yellow colour is reduced 
to purple formazan precipitate in living cells. Since the enzymes (reductases) that catalyse 
formazan formation from MTT are only active in living cells, the amount of formazan formed 
can be used as a measure of cell viability.Since formazan is insoluble in water, a 
solubilisation solution containing DMFO, SDS and Acetic acid is used to dissolve the 
formazan prior to measuring the absorbance at 570nm. MTT assays were performed on 
siRNA treated H441 and HMVEC-L in 24-well plates following standard protocols as a 
measure of cell viability following siRNA treatment. Following siRNA treatment, 75 µl of 
dye solution (Promega, Madison, MI) was directly added to each well. After incubation at 
37oC for 4 hours, 500 µl of solubilisation solution (Promega) was added and mixed well. 
Absorbances at 570nm of the contents of the well were recorded and levels compared 
between siRNA treated and untreated cells. 
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2.8: Analysis of H441 cell line for mutated Mig-6 
Materials:  
- TOPO TA cloning kit (Invitrogen) 
- OneShot E.coli cells (Invitrogen) 
- LB Broth from LB broth base powder (Invitrogen) 
- LB agar plates from LB agar powder (Invitrogen) 
- X-gal (Invitrogen) 
- Ampicillin (Invitrogen) 
- Agarose (Fisher Scientific) 
- 5x TBE 
o 53g Tris base (Fisher Scientific) 
o 27.5g boric acid (Fisher Scientific) 
o 20ml of 0.5M EDTA (Fisher Scientific) 
o Make up to 1L with water 
- Blue loading dye (Promega) 
- 0.5mg/ml Ethidium bromide (Sigma) 
- Power supply 
- Agarose gel electrophoresis tank 
- Microwave 
- Conical flask 
- 10x high fidelity PCR buffer (Invitrogen) 
- dNTP mix (Invitrogen) 
- 50mM MgCl2  (Invitrogen) 
- Primers: 
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o Mig-6 code F&R (Invitrogen) 
o Mig-6 code UTR F&R (Invitrogen) 
- Platinum high fidelity Taq (Invitrogen) 
- QIAprep Miniprep kit (QIAGEN) 
- Microcentrifuge 
- Microcentrifuge tubes 
- Tubes for LB broth 
- SOC medium (Invitrogen) 
- Peltier thermal cycler (MJ Research) 
- 1kb DNA ladder (New England Biolabs) 
- EcoR1 restriction enzyme (Invitrogen) 
- EcoR1 restriction buffer (Invitrogen) 
- UV spectrometer 
2.8: Analysis of H441 cell line for mutated Mig-6 
We decided to sequence the Mig-6 gene in the H441 cell line we were using to ensure that it 
contained no mutations. If the H441 was found to be mutated we wouldn’t be able to use it 
for Mig-6 functional studies. To determine whether H441 cells carried a mutated Mig-6 
allele, we performed a cloning reaction and sequenced all the products. 
The cells were grown to a confluency of ~70% in the tissue culture core at Baylor College of 
Medicine. RNA was isolated from cells and quantified as described in section 2.4. Isolated 
RNA was reverse transcribed to cDNA as detailed in section 2.5.  
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2.8.1: Mig-6 PCR: 
The cDNA was used as a template for amplification of the Mig-6 gene. Reaction volume was 
50µl which was made up of the following components: 5µl 10x high fidelity PCR buffer, 1µl 
10mM dNTP mix, 2µl 50mM MgCl2 , 0.2µl Platinum Taq High Fidelity, 0.5µl forward 
primer(10µM), 0.5µl reverse primer (10µM), 3µl template DNA and 37.8µl water. 
All primer sequences used in this experiment were designed using Vector NT1 Advance 10 
software from Invitrogen. Primers were synthesised by Invitrogen and sequences are shown 
in Table 2.2. Gene amplification consisted of an initial denaturation step where reaction 
mixtures were incubated at 94oC for 2mins. This was followed by 30 cycles of denaturation at 
94ºC for 30 seconds, annealing at 55oC for 30 seconds and extension at 68ºC for 2 minutes. 
All amplifications were carried out in a Peltier thermal cycler (MJ Research) 
Primer Sequence 5’-3’ Product 
Size (bp) 
Annealing 
Temperature 
Magnesium 
concentration 
Mig-6 
Code F 
 
ATGTCAATAGCAGGAGTTGC 
 
 
1386 
 
 
55oC 
 
5mM 
Mig-6 
Code R 
 
CTAAGGAGAAACCACATAGGAT
 
5mM 
Mig-6 
Code UTR 
F 
 
ACAGGTTTGGAGATGTCCCA 
 
 
1466 
 
 
55oC 
 
5mM 
Mig-6 
Code UTR 
R 
 
GAGAACCATTTGCTCCTATG 
 
5mM 
Table 2.2: Primer sequences, amplicon size, MgCl2 concentration and annealing temperature 
for Mig-6 PCR reactions. 
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Amplicons were visualised following electrophoresis using a 1% (w/v) agarose gel stained 
with ethidium bromide (0.5 µg/ml) in a 1 X Tris-Borate-EDTA (TBE) buffer.  A 1kb DNA 
ladder (New England Biolabs ) was run alongside the samples in order to determine amplicon 
size. The gel was run at a constant voltage (100V) until the bands had migrated about 1/2 to 
2/3 of the distance to the end of the gel. The resulting bands (~1.4kb) were visualised and 
then cut out (in order to gel purify the DNA). 
Making the 1% agarose gel: 
1g of low melting point agarose powder was dissolved in 100ml of 1X TBE buffer in a 
conical flask and microwaved for approximately 90 seconds. When it was determined that the 
agarose was fully dissolved, the flask was allowed to cool to ~60oC. Once the mixture had 
cooled, 50µl of ethidium bromide was added and the flask swirled to mix. The agarose was 
poured into the gel mould and allowed to set. Prior to loading, the comb was removed. 
Samples were prepared for loading by the addition of 10µl of 5x loading dye to a 50µl 
sample volume. The entire volume was loaded onto the gel alongside the 1kb ladder. 
 
2.8.2 DNA Purification from agarose gel: 
DNA was purified using the QIAEX II gel extraction kit from QIAGEN as follows: the band 
was cut from the gel using a blade and its weight recorded (this determines how much of the 
buffers to add in the purification process). The gel was dissolved in 450µl QX buffer and 
15µl of resin was added. The mixture was vortexed and placed on a heating block at 40-50oC 
for a total of ten minutes, vortexing the sample every two minutes. The sample was 
centrifuged for ~15 seconds to pellet the resin, the supernatant was removed, 500µl of fresh 
buffer was added and the mixture vortexed to resuspend the resin. Sample was centrifuged to 
pellet the resin followed by adding 500µl of wash buffer, vortexing to resuspend the pellet 
and centrifugation (~15 seconds). This wash step was then repeated. Following the second 
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wash step, the supernatant was removed and the pellet air dried at room temperature until 
most of the resin had turned white. 15µl of deionised water was added, the sample vortexed 
and then incubated at 50oC for five minutes. Sample was centrifuged to pellet and entire 
supernatant was transferred to a fresh tube. This purified DNA was used for the TOPO® 
cloning reaction.  
 
2.8.3 TOPO® Cloning Reaction 
The following reaction mixture was prepared: 2µl of gel purified DNA, 1µl salt solution 
(from the TOPO TA cloning kit), 2µl sterile deionised water and 1µl of TOPO vector 
containing DNA ligase. The mixture was incubated for five minutes at room temperature and 
then placed on ice in preparation for the transformation reaction.  
Transformation procedure: 
One vial of One Shot E. coli cells per transformation were thawed out. 2µl of the TOPO 
cloning mixture prepared above was added to the E. coli and mixed. The reaction was 
incubated on ice for 30 minutes followed by heat shock for 30-45 seconds at 42oC. 250µl of 
room temperature S.O.C medium was added to the cells. This was incubated at 37oC for one 
hour with shaking for the duration. 50µl of the transformation reaction was spread onto pre-
warmed LB agar plates containing x-gal and 100µg/ml ampicillin. Plates were incubated at 
37oC overnight 
2.8.4 Analysis of positive clones: 
Following overnight culture, the LB plates were examined for evidence of positive clones 
(white colonies). A positive clone is one which has taken up the vector with our DNA 
inserted and hence the beta galactosidase gene in TOPO that ordinarily converts XGal into a 
blue product is disrupted. Tubes were prepared each containing 3ml of LB broth with 
100µg/ml ampicillin. Using a pipette tip, one colony was picked off the plate and this tip put 
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into one of the tubes containing LB broth with ampicillin. The process was repeated for all 
tubes. The tubes were incubated at 37oC overnight with constant shaking.  
 
2.8.5 Plasmid Isolation and DNA purification: 
The overnight broth cultures were spun down to obtain a pellet of bacterial cells and the 
supernatant discarded. Plasmid DNA isolation purification was carried out using the QIAprep 
Miniprep kit from QIAGEN. The bacterial pellet was resuspended in 250µl of buffer P1 and 
transferred in a microcentrifuge tube. 250µl of buffer P2 was added and mixed by inverting 
4-6 times. 350µl of buffer N3 was added and mixed by inversion (at this point the solution 
should become cloudy). Samples were centrifuged at 10,000 rpm for ten minutes. The 
supernatant was transferred to a QIAprep spin column. This was spun for ~60 seconds and 
the flow through discarded. To wash the sample, 750µl of buffer PB was added and the tubes 
spun at 13,000 rpm for 60 seconds. The flow through was once again discarded and tubes 
centrifuged for a further 60 seconds. The column was placed into a microcentrifuge tube and 
50µl of buffer EB was added, left to stand at room temperature for one minute and then 
centrifuged for one minute to elute the DNA. The DNA was quantified by UV spectrometry 
(OD260nm:OD280nm) and then three samples were sent for sequence analysis.  
When a sequence result was received the sequence was compared to the known Mig-6 gene 
sequence to see whether any mutations were present in the sequence from our H441 cells.  
2.8.6 EcoRI digestion of plasmid: 
Prior to sending the samples for sequence analysis, an EcoRI digestion was carried out to 
ensure that the correct insert was present. 2µl of plasmid DNA, 0.5µl EcoRI, 1µl of buffer 3 
and 6.5µl were mixed in a tube and incubated at 37oC for one hour. The samples were then 
run on a 1% agarose gel and resulting bands were visualised on a UV transilluminator. For 
samples with the correct insert present there were 3 different bands present (the Mig-6 
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sequence itself has an EcoRI site which is cut) bands are present at 4kb (the vector), 1kb and 
0.5kb (the insert).  
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3. Results  
To obtain our Mig-6d/d mice, Rosa26-Cre-ERT2 mice were crossed with Mig-6flox/flox (Mig-
6f/f) mice and the resulting Rosa26-Cre-ERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6f/f mice (2 
months old) were injected peritoneally with 1 mg of Tamoxifen for 5 days. These mice were 
further maintained for 4 months before analysis. At  six months old mice were sacrificed, 
lung tissue harvested, mRNA extracted and real time quantitative PCR for Mig-6 was carried 
out using 18s RNA as a control. 
3.1 Real time PCR to show knock-out of Mig-6 in Mig-6 -/- mice and induced knock-out 
of Mig-6 in Tamoxifen treated Cre+ d/d mice 
The aim of this experiment was to test whether the Tamoxifen treatment had been successful 
in inducing the knockout of Mig-6 in the Cre+ (Mig-6d/d) mice. We already know from 
previous experiments in our lab that Mig-6 is involved at the developmental stages of the 
lung (5) but we wanted to investigate what role, if any, Mig-6 has at the adult stage. The 
administration of Tamoxifen to Mig-6f/f and Mig-6d/d mice at 2 months old is the first stage in 
the process, if the Tamoxifen treatment is successful in knocking out Mig-6 in the Cre+ mice 
then we can study Mig-6 in the adult mouse. As a large proportion of Mig-6-/- mice die before 
reaching adulthood it is difficult to investigate Mig-6 beyond the neonatal period.  Cre-ERT 
is a functional Tamoxifen-dependent recombinase in cultured cells and transgenic mice. By 
controlling the time point at which the target gene is excised using an inducible Cre 
recombinase, it allows us to look at the role of the gene later in the developmental process or 
in adult life as well as allowing tissue specific excision of the gene of interest (26). 
The figure 3.1 below shows the relative expression of Mig-6 mRNA in our transgenic 
Tamoxifen treated mice compared to a wild type strain.  
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Significant differences were noted between the wild type mice and the knockout (-/-) mice as 
well as the Tamoxifen treated Cre+ (d/d) mice. The Tamoxifen treated Cre- (f/f) mice had 
Mig-6 levels significantly different to the knockout (-/-) and induced knockout mice. 
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, 
(*p<0.05).  
 
 
 
Figure 3.1: Quantitative real time PCR analysis of mRNA levels isolated from 6 month 
old Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for expression of Mig-6 
Once we successfully knocked out Mig-6 in these adult mice the next step was to carry out a 
number of experiments looking at: General lung morphology, molecular markers, size of 
alveolar spaces, sacrificing mice at different time points following the knockout of Mig-6.   
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+/+: wild type mice, -/-: Mig-6 knockout mice 
f/f: Cre- mice, d/d: Cre+ mice 
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3.2 Comparison of the morphology of Mig-6f/f and Mig-6d/d adult mouse lungs 
Mig-6 plays a role in lung development, highlighted by altered lung morphology/reduced 
airway space in Mig-6-/- mice (5). We investigated whether lung morphology is altered when 
Mig-6 is deleted in adult mice.   To do this, we examined whether morphological differences 
would be observed between the Mig-6f/f and Mig-6d/d mice. Mice were sacrificed at 
approximately six months of age and the lung tissue harvested. This tissue was processed to 
wax blocks in preparation for sectioning and staining. 4µm sections were cut using a 
microtome and stained using a haematoxylin and eosin stain to show general morphology. 
The H&E staining method involves application of the basic dye haematoxylin, which 
colours basophilic structures with blue-purple hue, and alcohol-based acidic eosin, which 
colours eosinophilic structures bright pink. 
 
     
Figure 3.2 
Panels A&B above show representative H&E stained lung sections from adult Mig-6f/f 
and Mig-6d/d mice.  
No morphological differences were observed between adult lungs obtained from Mig-6f/f and 
Mig-6d/d mice upon H&E staining. As the lungs were fully formed in the adult mice before 
BA  d/d f/f 
H&E 
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Mig-6 was knocked out it would seem that Mig-6 does not have any noticeable effect on lung 
morphology after the initial development stage.  
3.3 Adult Mig-6f/f and Mig-6d/d mice have normal airspaces 
 The next step after a general assessment of morphology of the lung sections by staining was 
to take a series of sections stained using H&E to measure the size of the airspaces in our 
RosaCreERT2 x Mig-6f/f mice. For comparison purposes we also measured sections from 
wild type (Mig-6+/+) and Mig6 knock out (Mig-6-/-) mice. It has previously been shown in our 
lab that Mig-6-/- mice have larger airspaces than Mig-6+/+ mice (5). We wanted to examine 
our induced knock out (Mig-6d/d) mice to see if there was any effect on size of airspace. All 
measurements were performed blind with respect to animal genotype.  
Mig-6+/+ and  Mig-6-/- measurements were in line with previous results from our lab and 
showed that Mig-6-/- mice have significantly larger airspaces than wild type (Mig-6+/+) mice. 
This indicates a role for Mig-6 in either the development of or maintenance of airspaces in 
lung. Interestingly, a significant difference in size was noted between the Mig-6-/- mice and 
all other genotypes examined, including our induced Mig-6 knockout model (Mig-6d/d). This 
is strongly indicative that Mig-6 plays an important role in lung development but expression 
of Mig-6 in the adult lung does not affect airway size. In line with this hypothesis, no  
significant difference was noted between Mig-6+/+, Mig-6f/f or Mig-6d/d mice. Statistics were 
performed using One Way ANOVA with a Bonferroni post hoc test (*p<0.05).  
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Fig 3.3. Alveolar space measurements were carried out on wild type (Mig-6+/+) and knock out 
(Mig-6-/-) mice as well as Tamoxifen treated Cre- (Mig-6f/f) and Cre+ (Mig-6d/d) mice. Mig-6-/- 
mice have significantly increased airspaces while the Tamoxifen treated mice (both Mig-6f/f 
and Mig-6d/d) have airspaces in line with wild type measurements (n=8). 
3.4 Expression of Pulmonary Epithelial Cell markers in Mig-6-/- vs. Mig-6+/+ 
After measurement of the alveolar spaces in our mice we found no difference at the 
morphological level. It was decided to then look at a number of different molecular markers 
to investigate whether any differences would be apparent at the molecular level of the lung 
epithelium in our Mig-6f/f vs., Mig-6d/d/ mice since there are noted differences between wild 
type and Mig-6-/- mice.  
*
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RNA was isolated from the lungs of wild type and Mig-6-/- mice in addition to the Mig-6f/f 
and Mig-6d/d mice and the levels of the following molecular markers analysed using real time 
PCR CCSP, T1 alpha, Muc5ac and SP-C. We analysed the marker levels in wild type and 
knockout mice alongside our Tamoxifen treated mice (f/f and d/d). Although we observed no 
phenotypic change in the Mig-6d/d mice we could not assume there would be no change at the 
molecular level following the deletion of Mig-6 in adult mice so we investigated the 
molecular markers. 
3.4.1 CCSP levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice 
CCSP is Clara cell secretory protein and a significant difference is seen between Mig-6+/+ and 
Mig-6-/- mice (5). CCSP is a protective lung protein which is believed to have antioxidant, 
immunomodulatory and anticarcinogenic properties (60). CCSP is a developmental marker 
involved in cellular differentiation in respiratory epithelium during development and early 
life (61). Mig-6-/- mice have decreased CCSP levels (5).  
Statistics were carried out on the data using One Way ANOVA with a Bonferroni post hoc 
test, *p<0.05. Sample size was between five and nine mice for each group (n=5-9). We found 
that there was a significant difference in the CCSP levels measured between our Mig-6f/f and 
Mig-6d/d mice after deletion of Mig-6 with the treatment of Tamoxifen. Despite the high 
variability between samples, this assay had sufficient numbers to show a significant decrease 
in CCSP expression in Mig-6d/d mice compared with Mig-6f/f controls 
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Figure 3.4: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig-
6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of Clara cell secretory protein 
(CCSP) 
3.4.2 T1 Alpha levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice 
T1 alpha levels increase in the lung throughout foetal development and is the first marker 
gene known to be expressed in the adult lung solely by the alveolar type I epithelial cell (62). 
As Mig-6 levels also increase and decrease at various stages in lung development we thought 
it would be interesting to look at T1 alpha levels in our different mouse populations to see 
whether the absence or presence of Mig-6 impacted on the level of T1 alpha present. 
There is a significant difference in T1 alpha levels between Mig-6+/+ and Mig-6-/- mice with 
Mig-6-/- having greatly reduced amounts compared with the wild type control. No significant 
difference in T1 alpha was measured between f/f and d/d mice, nor did T1 alpha levels in 
* *
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these mice differ from the wild type levels measured.   This is an interesting result to note as 
T1 alpha levels were not affected when Mig-6 is knocked out at the adult stage of life while if 
it is knocked out in the germline then the resulting Mig-6-/- mice. This would suggest that 
Mig-6 and T1 alpha expression are both linked within the developmental process but 
expression of T1 alpha is independent of expression of Mig-6 in fully developed adult lungs.  
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05 
(n=5-9).  
 
 
 
Figure 3.5: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig-
6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of T1 alpha 
 
*
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3.4.3 SP-C levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice 
SP-C is surfactant protein C and is found solely in the surfactant layer of the alveoli (63). It 
has been reported to have the following three functions:  
1: catalyze the formation of surface-associated three-dimensional structures at the air-liquid 
Interface, 2: assist in the transfer of lipids from the monolayer to form stacked multi-layer 
structures, and 3: act as protection against surfactant inactivation by serum proteins (64).  
Mechanical strain has been shown to increase SP-C levels (65).  
SP-C levels were analysed in our different transgenic mice and control wild type mice- Mig-
6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d. The only significant difference noted was between the 
Mig-6-/- mice and all three other genotypes. Because the only difference in SP-C levels was 
seen in mice where Mig-6 is knocked out prior to foetal development this may point to a link 
between Mig-6 and SP-C in the developmental stages of life. It may be that Mig-6 has a 
regulatory role and prevents overexpression of SP-C during development and when this 
control is removed SP-C levels increase greatly. Alternatively, in the absence of Mig-6 
expression the alveolar structures are under greater mechanical strain and that this may 
indirectly lead to elevated SP-C expression. As there was no significant change in SP-C when 
Mig-6 is knocked out post development it would appear that whatever role Mig-6 plays in 
controlling SP-C levels is present only early in life.  
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, 
*p<0.05(n=5-9).  
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Figure 3.6: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig-
6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of surfactant protein C (SP-C) 
 
3.4.4 MUC5AC levels in Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice 
MUC5AC is a gel-forming glycoprotein of gastric and respiratory tract epithelia that protects 
the mucosa from infection and chemical damage by binding to inhaled microorganisms and 
particles that are subsequently removed by the muco-cilary system (66). Hypersecretion of 
mucins including MUC5AC is seen in many airway diseases and results in impairment of 
muco-ciliary clearance and bacterial super infection (67).  
In our measurements we found that wild type mice have low levels of mucin MUC5AC but in 
knockout mice (Mig-6-/-) there is a dramatic increase in MUC5AC levels. The Tamoxifen 
*
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treated Mig-6d/d and Mig-6f/f mice had MUC5AC levels similar to those of the wild type 
mice. As levels of this mucin were not altered when Mig-6 was knocked out in the adult 
phase of life it would appear that the lungs of Mig-6d/d mice are phenotypically normal and 
not subject to excessive airway diseases (these results are for unchallenged mice). Statistics 
were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05(n=5-9).  
 
 
Figure 3.7: Quantitative real-time PCR analysis of mRNA levels isolated from adult Mig-
6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d lungs for the expression of mucin 5AC (MUC5AC) 
Overall result from measurement of molecular markers: in all cases there was a significant 
difference in levels between wild type and knockout mice. The induced knockout mice had 
similar levels of expression of MUC5AC, SP-C and T1alpha while CCSP levels in Mig-6d/d 
mice were significantly different to wild type mice and Mig-6f/f controls. 
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 Knocking out Mig-6 in adult mice appears to have had no effect on phenotype or the 
majority of molecular markers for normal lung function. This would suggest that the lungs in 
adult Mig-6d/d mice are essentially normal even when Mig-6 expression is ablated using 
Tamoxifen although our results indicate that CCSP expression moderately decreases in 
Mig6d/d mice that are indicative of minor lung abnormalities or dysfunction. Therefore it 
appears that Mig-6 exerts greater influence during the developmental stage of the lung. As 
Mig-6 is a stress induced gene it may also be important in the lung’s response to 
damage/hypoxia/other injury, in these cases we would hypothesise that a re-emergence of 
developmental pathways could occur. 
3.5 Silencing of Mig-6 expression in H441 epithelial lung cells using RNA interference. 
The fact that Mig-6 is expressed in adult lungs points to the conclusion that it must serve 
some purpose in adult mice but our results indicate that it does not appear to play a major role 
in lung morphology or lung function. In order to look at the potential role(s) Mig-6 might 
play in adult mice we used lung cell lines to investigate the effect of knocking down Mig-6 
expression in different cell types (both epithelial and endothelial cells).  
We decided to look at Mig-6 expression and function specifically in epithelial cells so we 
used the H441 epithelial cell line for this purpose. The pulmonary epithelium plays a vital 
role in the body through its role in gaseous exchange ensuring a constant supply of oxygen is 
available to all cells throughout the body. In addition to its role in gaseous exchange the 
pulmonary epithelium also has a number of other roles: It provides a protective barrier 
between the host and the outside environment, contributes to the maintenance of lung fluid 
balance, plays a role in the metabolism of endogenous mediators (68) and is capable of 
regeneration, allowing normal cell turnover and restoration of airway and alveolar functions 
after lung injury (69). Lung epithelium produces surfactant and several proteins which are 
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important as part of the immune defences of the body (14). Because of these roles we were 
interested in investigating what effect (if any) silencing Mig-6 expression in this specific cell 
type would have. 
These experiments would provide an in vitro model to investigate the role of Mig-6 in 
epithelial cells. Half of our cells would be treated with siRNA with the other half treated with 
a control siRNA that does not silence any known gene. Successful silencing of Mig-6 
expression in the treated cells would allow us to harvest RNA and proteins from these cells to 
examine what effects silencing of Mig-6 had on downstream elements of the signalling 
pathway and thus gain further insight into what role Mig-6 has in adult lung epithelial cells.  
The first step in looking at the role of Mig-6 in epithelial cells was to use siRNA to knock 
down Mig-6. Previous experiments carried out in my lab using different concentrations of 
siRNA showed 50nm to be a sufficient concentration to silence Mig-6 expression. Following 
successful knock down of Mig-6 in this cell type the goal was to look at various elements of 
downstream signalling pathways to see if removing Mig-6 has an effect. Mig-6 is a known 
negative regulator of EGFR (70, 71) so we chose to look initially at signalling from the 
EGFR.  
The graph below (figure 3.8) shows the result of real time quantitative PCR (qPCR) analysis 
on our siRNA treated and untreated H441 epithelial cells. RNA was extracted from the cells 
as detailed in the Methods (section 2.4) and converted to mRNA. Real time PCR was carried 
out for Mig-6 levels with 18s ribosomal RNA as a control. Significant difference was noted 
in Mig-6 expression when cells were treated with Mig-6 siRNA compared with cells treated 
with either no siRNA or siControl. No significant difference was noted between the cells 
treated with siControl and the cells not treated with siRNA indicating that the decrease in 
Mig-6 expression was due to the specific RNA interference activity of our siRNA. The 
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success of this experiment allowed us to continue our experiments and look at the effect that 
this silencing of Mig-6 has on elements of the EGF signalling pathway. 
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, (p<0.05).  
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Figure 3.8: Real time quantitative PCR to show successful knock-down of Mig-6 in H441 
cells using 50nm siRNA 
3.6 Silencing Mig-6 expression in HMVEC endothelial lung cells using RNA 
interference 
Endothelial cells play an important role in the lung as the cells which line the capillaries that 
surround the alveoli in a network of blood vessels. As branching of the airways occurs in the 
developmental stages each new bud is surrounded by a network of endothelial cells. It is 
likely that Mig-6 also plays a role in regulating endothelial lung cell function; therefore we 
chose to look at the role of Mig-6 in endothelial cells using the Human Microvascular 
Endothelial Cells (HMVEC) cell line as our model.  
The aim was to successfully silence Mig-6 in HMVEC cells using the same method as for the 
epithelial cells. We planned to measure the same elements of the signalling pathway as in the 
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epithelial cells and see if there were any similarities or differences in the effect knocking 
down Mig-6 has on epithelial cells vs. endothelial cells.  
The graph below shows the result of real time quantitative PCR analysis on our siRNA 
treated and untreated endothelial cells. RNA was extracted from the cells as detailed in 
section 2.4 and converted to mRNA. Real time PCR was carried out for Mig-6 levels with 
18s ribosomal RNA as a control. Significant difference was noted between the cells treated 
with Mig-6 siRNA and cells treated with either no siRNA or siControl. No significant 
difference was noted between the cells treated with siControl and the cells not treated with 
siRNA.   Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, 
p<0.05.  
Figure 3.9: Real time quantitative PCR showing successful knockdown of Mig-6 in 
endothelial cells using 50nm siRNA. Levels of Mig-6 mRNA were compared in cells treated 
with control siRNA, Mig-6 siRNA and untreated cells. 
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3.7 Knockdown of Mig-6 leads to changes in cell proliferation: MTT assay 
EGF signalling is involved in development of the lung and can activate downstream 
signalling, Ras-PI3K/Akt and Ras/MAPK and cross-talk with other growth factors such as 
TGF-β1 and HGF signalling which are all important in lung development (5). As Mig-6 plays 
a role in the EGF signalling pathway it is plausible to hypothesise that if Mig-6 is altered or 
silenced it may have an effect on the cells in which we silenced Mig-6 expression and the 
function of Mig-6 in these cells might be established on the basis of silencing the expression 
of Mig-6 using RNA interference. Moreover, Mig-6 deletion affects lung morphology during 
development which may be regulated by increased cell proliferation / cell death due to Mig-6 
expression. 
We carried out a cell viability (MTT) assay to look at whether knocking down Mig-6 in our 
epithelial cells and endothelial cells has any effect on cell viability and if so would both cell 
types be affected in the same way or differently.  
The MTT assay is a cell viability assay in which MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide), usually a yellow colour is reduced to purple formazan in 
living cells. Since formazan is insoluble in water, a solubilisation solution containing DMFO, 
SDS and Acetic acid is used to dissolve the formazan prior to measuring the absorbance at 
570nm. Since the enzymes (reductases) that catalyse formazan formation from MTT are only 
active in living cells, the amount of formazan formed can be used as a measure of living cells 
(72). By looking at this type of assay we can see in vitro how cellular proliferation is affected 
and get some idea of how different cell types would be affected by lack of Mig-6 in vivo. 
Increased numbers of viable cells may indicate increased proliferation while a decrease in 
viable cells may be an indication that knocking down Mig-6 leads to increased apoptosis or 
decreased cellular proliferation. Results in Figure 3.10 below show that following 
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knockdown of Mig-6 in the epithelial cells, there was a significant increase in the amount of 
viable cells present when the MTT assay was performed which may point to increased 
cellular proliferation or cell survival in this cell type. The opposite pattern was observed in 
the endothelial cells with significantly decreased numbers of viable cells present following 
knock down of Mig-6 by siRNA treatment. This may suggest that lack of Mig-6 in 
endothelial cells leads to increased apoptosis or decreased cellular proliferation.  
Statistics were performed using One Way ANOVA with a Bonferroni post hoc test, *p<0.05.  
 
 
                      
Figure 3.10: Results of MTT (cell viability) assay in H441 epithelial cells and HMVEC 
endothelial cells showing increased levels of viable epithelial cells and decreased levels of 
endothelial cells following treatment with 50nm siRNA 
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3.8 Analysis of H441 cell line for mutated Mig-6 
To ensure that the H441 epithelial cell line we were using did not contain any mutations in its 
Mig-6 gene, we chose to sequence Mig-6 expressed by this cell line. It was important that no 
mutations were present as we were using this cell line for a large number of our experiments 
and should there be any mutations in its Mig-6 then our data would prove to be compromised. 
To investigate our H441 cells we isolated RNA and amplified the Mig-6 sequence using 
primers designed in house. We carried out a cloning reaction and sent the products for 
sequencing. Analysis of the sequencing results showed that no mutations were present in the 
Mig-6 gene in our H441 cell line.  
H441 cells were cultured and the RNA isolated once the cells were at ~70% confluency. RT-
PCR was performed followed by Mig-6 PCR. Two sets of primers were used in the Mig-6 
PCR- Mig-6 code and Mig-6 UTR. Mig-6 code is used to amplify only the coding region of 
Mig-6 while Mig-6 code UTR also amplifies the untranslated region. The Mig-6 code UTR 
therefore is a larger size as it incorporates both the translated and untranslated regions. 
PCR product was run on a 1% agarose gel and photographed as follows: 
 
 1        2         3    1. Mig‐6 code UTR 
2. Mig‐6 code 
3. DNA ladder
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Fig 3.11 Shows the result of the Mig-6 PCR. Lanes 1 & 2 shows the band produced using the 
Mig-6 specific primers designed in house at ~1.5Kb and lane 3 shows the DNA ladder loaded 
on the gel.  
3.8.1 ECOR I digestion of plasmids 
Prior to sending our clones for sequencing we carried out a digestion using ECORI to prove 
that the clones we were sending contained the correct insert. We firstly carried out our 
cloning reaction using a TOPO TA Cloning® Kit with pCR®2.1-TOPO® as our vector. 
Sequencing results showed no mutations in the Mig-6 sequence of our H441 cells. 
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 1.5 kb 
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Fig 3.12 shows the results of ECOR I digestion of the plasmids. The bands at 4 kb are the 
vector whilst the bands at 1kb and 0.5kb are the Mig-6 sequence (the sequence itself contains 
an ECOR I site so we get three bands when a digestion has been successful). 
Lane 1: 1kb DNA ladder 
Lanes 2-15: plasmids 1 to 14 
3.9 Western blot analysis of siRNA treated and untreated cells 
The aim of our procedures was to look at the proteins involved in the EGF signalling pathway 
and ascertain whether their levels were altered when we silenced Mig-6 using siRNA 
treatment. We were also interested in looking at the involvement of Mig-6 in the HGF 
signalling pathway. It is already known that Mig-6 has a negative effect on HGF/Met-induced 
cell migration. In addition to this is has previously demonstrated that Mig06 expression is 
induced by HGF stimulation (73).    
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3.9.1 HGF Induction of Mig-6 in H441 and NHBE cells 
This experiment was designed to look at the effect of HGF on cells where Mig-6 had been 
knocked out using siRNA. 40ng/ml HGF (hepatocyte growth factor) was administered for 
varying amounts of time and proteins isolated for Western blot analysis. The hypothesis was 
that if Mig-6 is involved in HGF signalling pathways then levels of Mig-6 proteins should 
change once HGF has been administered to the cells. We used H441 cell line as our epithelial 
cell model but also used NHBE (normal human bronchial epithelial) cells in our experiments 
so we would have data from both an epithelial cell line and from primary epithelial cells.  
HGF Induction of Mig-6 in H441 cells: 
We were unable to obtain any data for actin as a control so the densitometry analysis in this 
case will be a crude look at the changes occurring in this experiment assuming that the 
amount of protein loaded into each well was equal. We used the 0 min time point as a 
baseline to compare our other values to. An initial two-fold increase was observed at the 15 
min timepoint. At 30mins post HGF administration, Mig-6 dropped to about ½ that of the 
initial baseline level. At 2hrs post administration, mig-6 levels were ~3times that of the initial 
level and further increased to 4 times baseline by the 4 hour mark. 
The administration of 40ng/ml HGF appears to have a stimulatory effect on the production of 
Mig-6 in H441 cells. Without an Actin loading control, we cannot normalize for the 
variability in the amount of protein loaded into each lane. The experiment would need to be 
repeated using our optimised Western blot protocol ensuring an Actin or other protein control 
is included to more accurately assess how Mig-6 levels are affected upon HGF 
administration. 
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Fig 3.13a Shows the changes in Mig-6 levels in H441 epithelial cells observed at different 
time points post administration of 40ng/ml HGF (hepatocyte growth factor) 
 
 
Figure 3.13b Densitometry analysis of western blot (fig 3.13a) 
HGF Induction of Mig-6 in NHBE cells 
Analysis of the Western blot by densitometry was carried out in order to look at what effects 
administration of HGF would have on different protein levels in NHBE cells. We normalized 
Mig-6 and EGFR expression using Actin as our control for equal protein loading.  
Analysis showed little change in EGFR expression following treatment with HGF (as 
expected since HGF does not bind to EGFR) whereas changes in Mig-6 levels were clearly 
evident. Mig-6 expression quickly increased in expression and seemed to plateau after about 
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30 minutes to 1 hour.Mig-6 expression increased dramatically (~3 fold) between 15 minutes 
and 30 minutes post HGF administration. This dropped slightly to 2 ½ times the initial level 
at 1 hour before rising to almost four times the initial level at 2 hrs and dropping back to 2 ½ 
fold again at the four hour time-point.  
This experiment would need to be repeated to see if this pattern would be repeated or not. It 
would also be interesting to look at other elements of the HGF pathway to see what effects 
administration of HGF would have on these and whether any of these elements is having any 
influence on the Mig-6 pattern observed in NHBE cells.  
    0min 15min          30min            1h                  2h                  4h 
 
 
 
Fig 3.14a Shows the changes in Mig-6 and EGFR levels in normal human bronchial 
epithelial (NHBE) cells observed at different time points post administration of 40ng/ml HGF 
using actin as a loading control 
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Figure 3.14b: densitometry analysis of fig. 3.14a 
3.9.2 EGF Induction of Mig-6 in H441 and NHBE cells 
As Mig-6 has been shown to be a negative regulator of EGFR we wanted to look at the effect 
of administering 40ng/ml of EGF to siRNA treated cells. Following this we also planned to 
look at the downstream elements of the EGF signalling pathway. First we established the 
effects of EGF on Mig-6 expression in cells.  
EGF Induction of Mig-6 in H441 cells: 
Unfortunately, since we do not have an Actin control we cannot normalize our Mig-6 
expression levels to the exact amount of protein loaded in each lane. However, since we 
quantified the protein concentration in each sample and attempted to load equal amounts of 
protein into each lane we can establish that expression of Mig-6 appears to be sensitive to 
EGF. 
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Fig 3.15a Shows the changes in Mig-6 levels in H441 cells observed at different time points 
post administration of 40ng/ml EGF (epidermal growth factor) 
 
Figure 3.15b Analysis by densitometry showed that an initial decrease was observed post 
EGF administration but by the 1 hour mark, Mig-6 levels began to steadily increase. By the 4 
hour time-point a two fold increase in Mig-6 is clearly evident. 
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EGF Induction of Mig-6 in NHBE cells 
    0min 15min          30min            1h                  2h                  4h 
A   
B   
  C  
Fig 3.16a Shows the changes in Mig-6 and EGFR levels in normal human bronchial 
epithelial (NHBE) cells observed at different time points post administration of 40ng/ml EGF 
(epidermal growth factor). Blot B: Shows EGFR levels at several time points following the 
administration of 40ng/ml EGF. C shows the Actin control blot. 
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Figure 3.16b Analysis of the blots in fig 3.16a show that over the duration of the experiment, 
the levels of EGFR have remained relatively the same whilst the levels of Mig-6 have 
increased and decreased at different time points. The blots were normalised to Actin to allow 
for any loading differences.  
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Levels of Mig-6 began to rise from the 15 min point onwards with a large decrease occurring 
at 1 hour post EGF administration. This dip was then followed by a steady rise in levels at the 
remaining time points.  
3.9.3 p-Akt levels in H441 cells in the presence and absence of EGF 
 
 
 
 
 
Fig 3.17a shows Western blot analysis for p-Akt in H441 cells treated with 50nm siRNA in 
the absence and in the presence of EGF 
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Figure 3.17b Analysis by densitometry showed that in the presence of 40ng/ml EGF, there 
was an increase in p-Akt levels in all our siRNA treated cells. 
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This experiment was designed to look at some of the elements of the EGFR signalling 
pathway in epithelial cells where Mig-6 has been knocked down. Half of the cells were 
subjected to siRNA treatment alone while the other half were treated in the presence of EGF. 
In the cells where not EGF was added it appears that there is an increase in p-Akt levels 
where Mig-6 has been knocked down using siRNA compared to the control where Mig-6 is 
expressed. In the cells where EGF has been administered, there appears to be no real 
difference between the levels of p-Akt in the control and siRNA treated cells.  
The above blot (figure 3.17a) shows that in the cells treated with 40ng/ml EGF there appears 
to be increased p-Akt levels compared with the cells not treated with EGF.  
 
The Western blot section of our experiments did not yield much data as we spent much of our 
time attempting to optimise our protocols to obtain useable data. We tried a number of things 
in order to optimise our protocol including: 
1. Switching our washing buffer from PBST to TBST. 
2. Changing our blocking buffer from 1% milk in PBST to 5% milk in TBST, also we 
switched from blocking at room temperature for one hour to a brief rinse in the new 
blocking buffer. 
3. Altering the concentrations of both our primary and secondary antibodies and diluted 
them in 5% milk in TBST instead of 1% PBST. 
4. We reduced the length of our washing steps from ten minutes to eight minutes. 
These changed yielded better blots and would allow our lab to be able to repeat our 
experiments and yield useful data on the proteins involved in the signalling pathways of 
interest. The optimisation of the Western blot protocol was successful at the end of my 
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time in the lab but shown below (fig3.18) is an example of the result obtained using the 
new western blot protocol. 
In the experiment below we treated the H441 cells with siRNA for 72hrs as detailed in 
section 2.1. After siRNA treatment we harvested RNA for real time PCR analysis and protein 
for Western blot analysis. As figure 3.18 below shows we successfully knocked down Mig-6 
expression. This is illustrated again by the Western blot images above confirming the reduced 
expression of Mig6 in siRNA treated cells only.  
 
                
 
 
Fig 3.18a Western blot showing silencing of Mig-6 in H441 epithelial cells using 50nm 
siRNA 
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Figure 3.18b  densitometry analysis of figure 3.18a indicated that there was a 99% decrease 
in Mig-6 levels when cells were treated with 50nm Mig-6 siRNA. 
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4. Discussion 
Our lab was interested in studying the role of Mig-6 in the normal situation and in 
pathological conditions. By understanding the normal role that this gene plays we can gain 
greater insight to the processes that lead to disease when this gene is either deficient or 
completely absent. We proposed to carry out a number of different experiments in order to 
achieve our aims. Our studies were divided into animal studies and in vitro cell based studies.  
Studies have previously been carried out to look at how Mig-6 is involved in the normal 
development of the lung and what happens when it is absent. We chose to look at the role of 
Mig-6 in an adult population of mice. An inducible knock out model was created for this 
purpose by crossing Rosa26-Cre-ERT2 (74) mice with Mig-6 flox/flox mice resulting in either 
Rosa26-Cre-ERT2; Mig-6flox/flox (Mig-6d/d) or Mig-6flox/flox (Mig-6f/f) mice. Upon 
administration of Tamoxifen to Mig-6d/d mice Mig-6 was knocked down. This provided us 
with adult mice lacking the Mig-6 gene and afforded us the opportunity to look at any effects 
that this would have on these mice, using the Mig-6f/f mice as a control.  
Our in vitro studies looked at an epithelial cell line and an endothelial cell line. Using siRNA, 
Mig-6 expression was successfully silenced in both cell types. In these cells we looked at cell 
viability following Mig-6 silencing. We also intended to look at elements of the EGF 
signalling pathway and how they are affected by silencing Mig-6 expression.  
Our initial experiments focused on the inducible knock out model. Once the Tamoxifen 
treated mice had reached six months in age (4 months post Tamoxifen treatment) they were 
sacrificed and the lung tissue harvested. Some of the harvested tissue was processed to 
paraffin wax blocks and set aside for histological staining. The rest of the tissues were used 
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for molecular studies. mRNA was extracted and used for real time quantitative PCR analysis 
for Mig-6, CCSP, T1-alpha, SP-C and Muc5ac using 18s rRNA as a control. 
Figure 3.1 shows the results of the real time quantitative PCR analysis of Mig-6+/+, Mig-6-/-, 
Mig-6f/f and Mig-6d/d mice for Mig-6 RNA. We expected that Tamoxifen treatment would 
cause the ablation of Mig-6 in adult Mig-6d/d mice. Rosa26-Cre-ERT2 mice were crossed 
with Mig-6 flox/flox (Mig-6f/f) mice resulting in our Mig-6d/d mice. As expected, administration 
of Tamoxifen to both of these populations of mice resulted in the successful ablation of Mig-
6 in the Mig-6d/d mice while Mig-6 expression was similar to normal adult levels in the Mig-
6f/f control mice. In this important experiment to test our conditional knockout model, we 
demonstrated that expression of Mig-6 was comparable between wild type mice and Mig-6f/f 
mice and between Mig-6-/- mice and Mig-6d/d mice. Therefore, this allowed us to use our 
inducible knockout model to study the effects that the loss of Mig-6 would have (if any) in 
adult mice.  
Comparison of the morphology of f/f and d/d adult mouse lungs 
It has been shown previously in our lab that Mig-6-/- mice exhibit altered lung morphology 
(increased alveolar spaces and altered septation compared with wild type mice (5). However, 
Mig-6 expression is ablated from conception in Mig-6-/- mice which hinders our efforts to 
elucidate the role of Mig-6 in adult mice. Therefore, we chose to carry out a set of 
experiments to compare lung morphology in Tamoxifen treated Mig-6f/f and Mig-6d/d mice. 
Lung sections from our Tamoxifen treated mice were stained using Haematoxylin and Eosin 
to show general morphology. Both the Mig-6d/d and Mig-6f/f mice showed normal lung 
morphology and no differences were noted between the two genotypes. Measurement of the 
alveolar spaces of Mig-6+/+, Mig-6-/-, Mig-6f/f and Mig-6d/d mice showed that while the Mig-6-
/- had significantly larger alveolar spaces, specific depletion of Mig-6 in adult mice (Mig-6d/d) 
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using Tamoxifen did not lead to any significant differences in alveolar size when compared to 
wild type mice and Mig-6f/f mice. 
Results of the histological analysis shows that when Mig-6 is ablated in adult mice using 
Tamoxifen, the lung tissue remains morphologically similar to the wild type untreated mice. 
These mice were at the adult stage of life and therefore their lungs were fully formed before 
treatment to induce ablation of Mig-6 commenced. Our results appear to indicate that once 
lung development is complete, Mig-6 may not have any noticeable effect on lung 
morphology.  
Pulmonary markers-CCSP, SP-C, T1 alpha, Muc5ac 
There is a significant difference in T1 alpha levels between Mig-6+/+ and Mig-6-/- mice with 
Mig-6-/- having greatly reduced expression of T1 alpha in the lung (see Figure 3.5). No 
significant difference in T1 alpha expression in the lung was measured between f/f and d/d 
mice, nor did T1 alpha levels in these mice differ significantly from the wild type levels 
measured.   This is an interesting result to note as T1 alpha levels were not affected when 
Mig-6 is knocked out at the adult stage of life while if it is knocked out in the germline then 
the resulting Mig-6-/- mice have significantly reduced T1 alpha levels, this may point to a 
decrease in type I airway epithelial cells as T1 alpha is used as a marker for this cell type. Our 
data indicate that Mig-6 and T1 alpha expression are both linked within the developmental 
process and that defective lung development in Mig-6-/- mice may contribute to the 
decreased expression of this important alveolar type I epithelial cell.  
SP-C levels in Mig-6-f/f and Mig-6d/d mice are unchanged from those seen in wild type levels 
while levels in Mig-6-/- mice are greatly elevated. Because the only difference in SP-C levels 
was seen in mice where Mig-6 is knocked out prior to foetal development this may point to a 
link between Mig-6 and SP-C in the developmental stages of life. It may be that Mig-6 has a 
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regulatory role and prevents overexpression of SP-C during development and when this 
control is removed SP-C levels increase greatly. It is interesting to note that SP-C expression 
has been found to increase when mechanical strain in the lung is increased (65) SP-C can be 
used as a marker for typ1 II epithelial cells so it may be that in mechanical strain on the lung, 
type II airway epithelial cell expression is increased. Lung morphology has developed 
normally in the Tamoxifen treated Mig-6d/d mice and no increase in SP-C was observed, 
suggesting that Mig-6 expression does not directly control SP-C levels.  However, SP-C is 
greatly elevated in the lungs of Mig6-/- mice suggesting that the increased SP-C expression 
observed here may be due to increased mechanical strain as a consequence of developmental 
defects in the lung morphology of Mig6-/- mice. Further investigations would be needed to 
confirm or disprove this hypothesis.  
MUC5AC levels in Mig-6-f/f and Mig-6d/d mice are not significantly different to that of wild 
type mice. The Mig-6-/- mice on the other hand had a dramatic increase in MUC5AC. This 
would suggest that MUC5AC levels may be linked with Mig-6 at a developmental stage but 
not once the lungs have been formed as in our Mig-6-f/f and Mig-6d/d mice. As previously 
mentioned, MUC5AC levels have been seen to be increased in airway disease (75) while 
decreased Mig-6 levels are often seen in airway disease. This might suggest that there could 
be a regulatory link between Mig-6 and MUC5AC.  
In the case of the CCSP measurements, it appears as though the Mig-6d/d group express about 
half the levels of CCSP compared with the wild type and Mig-6f/f mice. However, there was a 
large degree of variability noted in these measurements so despite obtaining significant 
differences, we would need to repeat this experiment to increase our confidence in our data 
for this marker. However, one must also consider the possibility that Mig-6 expression plays 
a role in regulating some functions of Clara cells in adult mice. If CCSP expression is 
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consistently decreased in Mig-6d/d mice, then further experimentation should be carried out to 
determine the role of Mig-6 in promoting CCSP expression.  
Measurement of the molecular markers in our different mouse genotypes provided some 
interesting results. In all four cases there was a significant difference noted between wild type 
and Mig-6 knockout mice. In all but the CCSP measurements, no significant difference was 
noted between our two genotypes of Tamoxifen treated mice. These levels were also 
comparable to the wild type measurements obtained at the same time. These data seem to 
indicate that Mig-6 does not directly regulate the expression of SP-C, T1 alpha and 
MUC5AC in adult mouse lung cells.  
In repeating the experiment we would also increase the number of animals of each genotype 
tested account for this variability and this would allow us to be more confident that our 
results would accurately represent the genotypes in question. 
In vitro cell studies 
The next set of experiments was designed to allow us to look at the effect of Mig-6 in specific 
cell types in vitro and gain a greater insight into the signalling pathways that are influenced 
when Mig-6 is knocked out. We looked at an epithelial cell line and an endothelial cell line to 
ascertain whether any differences would be noted when we knocked out Mig-6 in these cell 
types or whether the same signalling pathways would be affected in both cell types. 
The first step was to use RNA interference to knock out Mig-6 expression. This was 
successfully achieved using a concentration of 50nm siRNA. RNA was extracted from the 
treated cells and real time quantitative PCR analysis for Mig-6 showed that we were 
successful in silencing Mig-6 expression in both cell lines (See Figure 3.8 and 3.9). 
Following this we moved onto the next set of in vitro experiments. We carried out a cell 
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viability assay to look at whether silencing Mig-6 expression would have any effect on the 
viability of the cells. Interestingly, our results showed that the number of viable epithelial 
cells increased following silencing of Mig-6 expression using siRNA while cell viability was 
seen to decrease when Mig-6 expression was silenced in endothelial cells.  
We hypothesised from these results that in an epithelial cell population, silencing Mig-6 
expression may cause an increase in cellular proliferation which would explain the increase 
in viable cells measured. Another potential reason for the increased viable cells could be that 
in the absence of Mig-6, regular cell death does not occur at the same rate as normal resulting 
in increased cellular survival.  
A decrease in viable cells was observed when Mig-6 expression was silenced in endothelial 
cells. This led us to hypothesise that there was increased apoptosis in this cell population or 
that there was a decreased rate of cellular proliferation. To investigate this further we could 
use imunohistochemical staining for cleaved caspase 3 to look at apoptosis. 
This may be linked to the pathways affected when Mig-6 is removed and our next step was to 
investigate these pathways by looking at various protein levels in cells where Mig-6 has been 
silenced as well as cells where Mig-6 levels remain as normal. Because Mig-6 is known to be 
involved in the EGF signalling pathway that was our initial focus to see how downstream 
elements would be affected upon silencing of Mig-6 expression. Activation of the EGF 
receptor results in activation of various downstream signalling cascades including the 
RAS/ERK pathway, the PI3K/Akt pathway and the JAK/STAT pathway which coordinate to 
promote cellular survival and proliferation (76).  
Mig-6 has been shown to be a negative regulator of EGFR signalling (30) so when it is no 
longer present then EGF receptor activation kinetics are prolonged and the above mentioned 
pathways (Ras/Erk; PI-3K/Akt; and JAK/STAT) may be activated for longer than normal 
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leading to changes in cellular survival. It was interesting to note that when Mig-6 was 
silenced it had differing effects on the survival of epithelial cells and endothelial cells. To 
understand potential reasons for this it was necessary to look at levels of the individual 
components of each signalling pathway involved to see at which point in the signalling the 
differences occurred.  
HGF signalling has also been linked to Mig-6 which led us to decide to look at what effect 
HGF signalling pathways would have on Mig-6 expression and related signalling pathways. 
We intended to look and both EGF-dependent and HGF-dependent induction of Mig-6 
expression in lung epithelial cells treated with siRNA alongside untreated cells. In particular, 
we were interested in whether administration of either EGF or HGF would significantly 
affect the levels of Mig-6 expression and if so how long it would take to occur. We used 
H441 cells again as our epithelial cell line but this time we also used NHBE cells as a 
primary epithelial cell line to gain data from both a cell line and primary human cells. In 
addition to investigating expression of Mig-6, we also intended to look at levels of various 
proteins following EGF/HGF administration using Western blot analysis. The protein levels 
we were interested include: total Akt and activated phospho-Akt (p-Akt), total mTor and 
activated p-mTor, total EGFR expression and activated p-EGFR.  
Initially we experienced difficulty in getting our Western blot protocol to work sufficiently 
and as a result spent a large amount of our time altering the protocol in an attempt to optimise 
it. The changes (altering buffers, blocking solution, changing antibody concentration and 
altering incubation times) yielded better blots and would allow our lab to be able to repeat our 
experiments and yield useful data on the proteins involved in the signalling pathways of 
interest. The optimisation of the Western blot protocol was successful at the end of my time 
in the time in the lab. Had there been more time we would have carried out our planned 
investigation of the proteins involved in the pathways I mentioned earlier. In addition to 
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looking at the changes seen at the protein level, it would also be interesting to look at any 
changes seen at the RNA level to obtain the full picture. From the limited data we obtained it 
appears that administration of EGF to Mig-6 siRNA treated cells can cause an increase in the 
Mig-6 protein levels between 1 and 4 hours post-administration of EGF. This experiment 
would need to be repeated to ascertain whether this is truly the case.  
Our results showed some interesting data which provides further routed of investigation of 
the role of Mig-6. Of particular interest were the results of the in vitro studies which showed 
differing effects on cell survival/proliferation when comparing lung epithelial and endothelial 
cells. The next step would be to use our improved Western blot protocol to obtain more data 
on the different proteins affected in both cell types following silencing of Mig-6. This would 
lead to a greater understanding of how these cells are affected in vitro and perhaps lead to 
further research into potential therapies to overcome the effects of a loss of Mig-6.  
Future directions for this research: 
As Mig-6 is a stress induced gene our lab is interested in looking at what happens when Mig-
6 is knocked out at the adult stage of life but this time exposing the animals to a stress (such 
as cigarette smoke for example) and examining whether this would show different effects 
than when we simply just knocked out Mig-6 in adult mice. In our experiments the lungs of 
induced knockout mice appeared to remain normal so it would be of interest to investigate 
whether the same would be true when the induced knockout mice were also exposed to stress.  
Because of the differences noted between effects on siRNA treated epithelial and endothelial 
cells, our lab is interested in pursuing this and looking in more detail at the role of Mig-6 in 
both types of cells. 
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This inducible knockout model would also be beneficial in studying the role of Mig-6 
expression in cancer, especially in light of its putative role as a tumour suppressor (2).  
By understanding the role that Mig-6 plays in the normal individual, we can gain a better 
insight into what happens when Mig-6 is absent and where things go wrong at a molecular 
level. This will enable the development of more treatment options and ways to overcome the 
effects which result from the absence of Mig-6. 
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